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Investigating the Role of ZNF384 Rearrangements in Acute Leukemia
Abstract
Chromosomal rearrangements involving ZNF384 are the defining lesion in 5% of pediatric and adult B-cell
acute lymphoblastic leukemia and tumors are characterized by aberrant myeloid marker expression.
Additionally, ZNF384 rearrangements are the defining lesion in nearly half of pediatric B/myeloid mixed
phenotype acute leukemia. These fusions juxtapose full-length ZNF384 to the N terminal portion of a
diverse range of partners, most often, transcription factors or epigenetic modifiers. It has been shown
that ZNF384-rearranged tumors have a distinct gene expression profile that is consistent between
disease groups and N terminal partners. Genomic analyses of patient tumors has shown that ZNF384
fusions arise in hematopoietic stem cells and that expression of the fusion, but not the concomitant
genetic alterations, results in lineage aberrancy, however, the mechanistic role of ZNF384 rearrangements
has not been formally studied. The goal of this project was to investigate the role of ZNF384
rearrangements, together with concomitant genetic alterations, in leukemogenesis, with an emphasis on
characterizing the role of cell-of-origin and lineage of the resulting leukemias. Additionally, I aimed to
explore the mechanism that leads to a distinct gene expression profile and immunophenotype.
Using viral overexpression and newly developed genetically engineered mouse models I have shown the
effect of ZNF384 fusion expression at multiple stages of hematopoietic development in mouse and
human systems. These experiments revealed the hematopoietic skewing toward immature, myeloid
differentiation caused by expression of ZNF384 fusions. While expression of ZNF384 fusion oncoproteins
in either mouse or human hematopoietic progenitors resulted in hematopoietic expansion, lineage
skewing, and for some fusion partners, self-renewal in vitro; co-expression with common concomitant
lesions, such as NRAS G12D, was necessary in order to develop a fully penetrant mouse leukemia in vivo.
In contrast, ZNF384 fusions alone drive B/myeloid leukemia when expressed in human hematopoietic
stem and progenitor cells and transplanted into NSG-SGM3 mice, highlighting the benefits of using
human models to investigate human oncogenes. Importantly, these experiments confirm that
hematopoietic stem cells are the most sensitive to cellular transformation by ZNF384 fusions.
Mechanistic studies integrating gene expression and chromatin occupancy data revealed that fusions
bind canonical ZNF384 sites with greater intensity than wild type protein. A subset of regions with
increased fusion binding also had increased H3K27Ac and were intronic or intergenic suggesting they are
putative enhancer regions.
These findings support that ZNF384 fusions occur in an early hematopoietic stem or progenitor cell
which leads to skewed hematopoiesis and leukemic transformation in the presence of additional lesions,
proliferative stress, or cytokine stimulation. This is likely caused by inappropriate extended activation of
stem and progenitor enhancer regions along with deregulation of lineage-specific genes by altered
binding of ZNF384 fusions. Together, these results demonstrate an intersection of cell of origin and
expression of fusion oncoproteins as necessary prerequisites for generating lineage ambiguous
leukemia.
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ABSTRACT

Chromosomal rearrangements involving ZNF384 are the defining lesion in 5% of
pediatric and adult B-cell acute lymphoblastic leukemia and tumors are characterized by
aberrant myeloid marker expression. Additionally, ZNF384 rearrangements are the
defining lesion in nearly half of pediatric B/myeloid mixed phenotype acute leukemia.
These fusions juxtapose full-length ZNF384 to the N terminal portion of a diverse range
of partners, most often, transcription factors or epigenetic modifiers. It has been shown
that ZNF384-rearranged tumors have a distinct gene expression profile that is consistent
between disease groups and N terminal partners. Genomic analyses of patient tumors has
shown that ZNF384 fusions arise in hematopoietic stem cells and that expression of the
fusion, but not the concomitant genetic alterations, results in lineage aberrancy, however,
the mechanistic role of ZNF384 rearrangements has not been formally studied. The goal
of this project was to investigate the role of ZNF384 rearrangements, together with
concomitant genetic alterations, in leukemogenesis, with an emphasis on characterizing
the role of cell-of-origin and lineage of the resulting leukemias. Additionally, I aimed to
explore the mechanism that leads to a distinct gene expression profile and
immunophenotype.
Using viral overexpression and newly developed genetically engineered mouse
models I have shown the effect of ZNF384 fusion expression at multiple stages of
hematopoietic development in mouse and human systems. These experiments revealed
the hematopoietic skewing toward immature, myeloid differentiation caused by
expression of ZNF384 fusions. While expression of ZNF384 fusion oncoproteins in
either mouse or human hematopoietic progenitors resulted in hematopoietic expansion,
lineage skewing, and for some fusion partners, self-renewal in vitro; co-expression with
common concomitant lesions, such as NRAS G12D, was necessary in order to develop a
fully penetrant mouse leukemia in vivo. In contrast, ZNF384 fusions alone drive
B/myeloid leukemia when expressed in human hematopoietic stem and progenitor cells
and transplanted into NSG-SGM3 mice, highlighting the benefits of using human models
to investigate human oncogenes. Importantly, these experiments confirm that
hematopoietic stem cells are the most sensitive to cellular transformation by ZNF384
fusions. Mechanistic studies integrating gene expression and chromatin occupancy data
revealed that fusions bind canonical ZNF384 sites with greater intensity than wild type
protein. A subset of regions with increased fusion binding also had increased H3K27Ac
and were intronic or intergenic suggesting they are putative enhancer regions.
These findings support that ZNF384 fusions occur in an early hematopoietic stem
or progenitor cell which leads to skewed hematopoiesis and leukemic transformation in
the presence of additional lesions, proliferative stress, or cytokine stimulation. This is
likely caused by inappropriate extended activation of stem and progenitor enhancer
regions along with deregulation of lineage-specific genes by altered binding of ZNF384
fusions. Together, these results demonstrate an intersection of cell of origin and
expression of fusion oncoproteins as necessary prerequisites for generating lineage
ambiguous leukemia.
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CHAPTER 1.

INTRODUCTION

Hematopoiesis
Hematopoiesis is the differentiation and expansion of cells in the bone marrow
from the most immature, uncommitted hematopoietic stem cell to more committed
progenitor cells and finally to the full range of mature cells that include the hematopoietic
system, red blood cells, and platelets. As cells progress through differentiation they can
become either lymphoid cells (B-cell, T-cell, or natural killer cell) or myeloid cells
(erythrocyte, megakaryocyte, granulocytes, monocytes, etc.). A properly functioning
immune system is essential for fighting infection, healing damaged tissue, and providing
our cells with oxygen and nutrients. Acute leukemia, one type of malignancy of the
blood, occurs when a hematopoietic cell acquires mutations in a stepwise progression that
disrupts multiple cellular pathways; which leads to a block in differentiation and rapid
expansion of immature cells. These cells take over the bone marrow and prevent normal
hematopoiesis from occurring which results in cytopenias; including leukopenia, which
result in susceptibility to infection; thrombocytopenia, which results in susceptibility to
bleeding and bruising; and anemia, which leads to fatigue and lethargy.

Acute Leukemia
Acute leukemias are subdivided into acute lymphoblastic leukemia (ALL), acute
myeloid leukemia (AML), or acute leukemia of ambiguous lineage (ALAL) according to
the World Health Organization (WHO) criteria that uses cell morphology, molecular
characteristics, expression of lineage specific cell-surface proteins (immunophenotype),
and cytogenetics1. Defining subtypes of leukemia has clinical relevance for the diagnosis,
prognosis, and treatment of patients.
ALL affects approximately 6,000 Americans each year, with over half of those
cases in children and young adults2. It is the most common cancer in children and though
the survival rate is greater than 90%, it remains one of the leading causes of cancer death
in children. Based on the immunophenotype, it can be of precursor B-cell (B-ALL) or Tcell (T-ALL) which make up 85% or 15% of ALL, respectively2. Numerous studies have
been published defining the genetic landscape of leukemogenesis and there are now wellestablished subtypes of ALL based on the presumed initiating lesion (Figure 1-1) that
have proven important for diagnosis, risk stratification, and in some cases, targeted
therapy.
Subtypes are commonly defined by structural chromosomal alterations,
specifically, aneuploidy or chromosomal rearrangements. There are two mechanisms by
which chromosomal rearrangements can disrupt normal gene function. One type of
rearrangements juxtapose an oncogene to an active enhancer which leads to high
expression of the intact oncoprotein. In B-ALL, the hijacked enhancers are commonly at
immunoglobulin receptor loci (i.e. IGH-CRLF2)3. Alternatively, the majority of

1

Figure 1-1. Genomic subtypes of acute leukemias.
A representation of the distribution of subtypes that drive pediatric acute lymphoblastic
leukemia (ALL), pediatric acute leukemia of ambiguous lineage (ALAL), or adult acute
myeloid leukemia (AML). ALL is subdivided into B-ALL and T-ALL. ALAL is
subdivided into T/myeloid (T/M), B/myeloid (B/M), KTM2A-rearrangement driven
(KTM2Ar), not otherwise specified (NOS), acute undifferentiated leukemia (AUL), or
Philadelphia chromosome (Ph+). Other, No class, and No drivers; leukemia lacking
recurrent abnormalities. Data sources: Gu Z, Churchman ML, Roberts KG, et al. PAX5driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019; 51(2):
296-307.4 Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of
mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373-9.16 Papaemmanuil E,
Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid
Leukemia. The New England journal of medicine 2016; 374(23): 2209-21.6.
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rearrangements bring two genes together which leads to the translation of a novel,
chimeric protein (i.e. ETV6-RUNX1)2. Rearrangements that can be identified by
conventional karyotyping (i.e. BCR-ABL1 and KMT2A-r) have been known for many
years, thus, functional experiments and models have been able to investigate the
mechanism. However, fusion genes that cannot be identified by karyotyping were only
recently discovered using next generation sequencing. There is a great need for modeling
these fusions to reveal the mechanism driving the subtype which can lead to improved
therapies. One of these newly identified subtypes is ZNF384-rearranged leukemia, which
makes up 3% of B-ALL and is characterized by the fusion of genes encoding
transcription factors or epigenetic modifiers to ZNF3844. Tumors also have 10 to 20
secondary lesions, often DNA copy number alterations and sequence mutations, that most
commonly affect genes important for lymphoid cell development and regulation, cellcycle regulation, TP53 (p53)-retinoblastoma pathway regulation, Ras signaling pathway,
JAK-STAT signaling, and epigenetic regulation2.
AML affects over 20,000 patients each year in the United States, mostly adults,
with the average age at the time of diagnosis being 65 years. Despite therapeutic
advances, cure rates remain below 40% and are very poor in the elderly population
(15%)5. AML is a genetically heterogeneous disease that is divided into subtypes based
on patterns of co-mutations, diagnostic features, and clinical outcomes (Figure 1-1)6.
Although, not common enough in AML to define a subtype, there have been multiple
case reports of ZNF384 rearrangement in primary or lineage-switched AML 7,8,9,10.
ALAL is a rare subtype of acute leukemia that includes leukemias lacking
commitment to any cellular lineages, acute undifferentiated leukemia (AUL), and
leukemias committed to more than one lineage, mixed phenotype acute leukemia
(MPAL)11. MPAL is further divided based on immunophenotype into either T-cell and
myeloid (T/myeloid) or B-cell and myeloid (B/myeloid)12. Survival rates are 47-75% and
20-40% for children and adults, respectively13-16. These poor survival rates are in part due
to the limited genomic characterization of this subtype which led to classification based
solely on immunophenotype and an inconsistent treatment protocol, using either ALL,
AML, or a combined protocol13,14,15. Several recent studies have begun to examine the
genomic basis of MPAL. Interestingly, the lesions identified were not unique to MPAL,
but also seen in ALL or AML, and present throughout the immunophenotypic
subpopulations of the tumors (Figure 1-1)16. Notably, ZNF384-rearrangements represent
43% of B/Myeloid MPAL and biallelic WT1 mutations were present in 41% of
T/Myeloid MPAL16. Additionally, founding lesions were identified in hematopoietic
progenitors and subpopulations of tumors were able to reconstitute the
immunophenotypic diversity in vivo; proving that the cell of origin, and not a
combination of lesions, is responsible for the lineage ambiguity 16. Together this
highlights the limitations of using the immunophenotype alone and the importance of
identifying the genetic driver when characterizing and classifying disease.
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Transcriptional Regulation of Hematopoiesis
Precise regulation of gene expression is essential during differentiation; thus, cells
have many mechanisms to maintain the correct expression of genes. At a chromatin level,
expression is regulated by how open or compact a region of DNA is. This process is
controlled by chromatin modifiers, which are proteins that directly modify DNA,
physically slide the histone proteins to promote opening or compaction of DNA, or
modify the histone proteins that DNA is wrapped around.
DNA methyltransferases (DNMTs) and DNA demethylases (TET family proteins)
add or remove, respectively, methylation marks on cytosine residues located within a
cytosine-guanine (CpG) sequence17. Multiple CpG sites create CpG islands. Gene
expression is repressed when CpG islands in the promoter region are methylated which
leads to DNA compaction18.
Chromatin remodelers are multi-subunit complexes that utilize ATP-hydrolysis to
move or remove histone proteins in order to alter chromatin structure. The
Switch/Sucrose non-fermentable (SWI/SNF) chromatin-remodeling complexes bind to
active promoters and make DNA more accessible whereas, imitation switch subfamily
(ISWI) remodelers compact DNA19. Additionally, there are complexes that specialize in
adding histones after DNA replication or exchanging the canonical histone H2A with the
variant H2A.Z. The recruitment of these remodeler complexes is regulated by the
combination of transcription regulator proteins and histone modifications at specific
regions of DNA19.
Nucleosomes are the cellular system for organizing and packaging DNA into
chromosomes. They are made of an octamer of histone proteins that are wrapped in
DNA. Histones have tails that protrude from the nucleosome and are subjected to posttranslational modifications, most commonly, acetylation and methylation of lysine
residues20. The specific combination of modified histone residues in a particular region of
DNA is referred to as the chromatin state and determines the potential for transcriptional
activity at that site. Research performed by many labs over the last 20 years has revealed
and validated this “histone code” which can predict the regulatory role of a region based
on the histone modifications present. The NIH Roadmap Epigenomics Consortium and
the International Human Epigenome Consortium (IHEC) define these patterns as
H3K4me3 (i.e. histone 3, lysine 4, trimethylation) and H3K27ac (i.e. histone 3, lysine 27,
acetylation) in promoter regions, H3K4me1 and H3K27Ac in enhancer regions,
H3K36me3 in transcribed regions, H3K27me3 in Polycomb repressed regions, and
H3K9me3 in heterochromatin regions21.
Addition, recognition, maintenance, and removal of modifications is performed
by three classes of enzymes; writers, readers, and erasers19. Acetyl marks are placed by
histone acetyltransferases (HATs), recognized by bromodomain-containing remodeling
factors, and removed by histone deacetylases (HDACs)19. Methyl marks are placed on
lysine residues by lysine methyltransferases (HKMTs), recognized by PHD domaincontaining factors, and removed by histone demethylases19.
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The next level of regulation is through transcription factors (TFs) that bind to
gene regulatory regions. These regions can be distal enhancer sites or the promoter
regions which are directly upstream of the gene. Each TF has a specific consensus
sequences of DNA that it binds in the regulatory regions, co-factors and transcriptional
machinery are then recruited, and together can activate or repress expression. Often, there
are lineage-specific TFs that guide cell fate by regulating expression of lineage-specific
genes22. An example of the importance of lineage-specific TFs during hematopoiesis is
PAX5, which simultaneously activates B-lymphoid-specific genes while repressing Blineage-inappropriate genes to restrict the developmental potential to the B cell
pathway23.
Over 40% of B-ALL cases, and nearly all MPAL cases, are defined by an
alteration in an epigenetic modifier or transcription factor4,16. These subtypes have
distinct gene expression profiles, especially, in comparison to aneuploidy or kinasedriven subtypes, which have heterogeneous gene expression4.

ZNF384-rearranged Leukemia
The first case of leukemia with a probable ZNF384-rearrangement was published
in 198224. At that time the genes involved were unknown and the alteration was referred
to by the chromosomal breakpoints. Over the next 20 years, there were numerous reports
of pediatric and adult leukemias harboring the t(12;17)(p13;q12) rearrangement and 1
patient with t(12;22)(p13:q11). In 2002 the genes involved in 12p13 rearrangements were
identified as TAF15-ZNF384 and EWSR1-ZNF3848. Later, another fusion partner,
TCF3, was identified using fluorescence in situ hybridization (FISH) and ZNF384rearranged leukemia began to emerge as a subtype of leukemia25. However, it is now
recognized that most ZNF384 rearrangements are cryptic and therefore, were only
recently identified using genomic analyses, particularly RNA-sequencing. Several groups
have published sequencing results from large cohorts of leukemias which have identified
multiple partners (ARID1B, ATP5C1, BMP2K, CLTC, CREBBP, EP300, EWSR1,
NIPBL, SMARCA2, SMARCA4, SYNRG, TAF15, and TCF3) that most often have an
N-terminal portion fused to full-length ZNF384 (Table 1-1). This combined effort has
validated that ZNF384 fusions define a subtype of leukemia with distinct clinical features
and gene expression profile (Figure 1-2). The most common breakpoint on ZNF384 is
exon 3, which is the first coding exon. Fusions are also commonly reported with the
breakpoint at exon 2 leading to inclusion of 22 novel amino acids. TCF3-ZNF384
occasionally has a breakpoint with exon 5 of ZNF384, which is missing the leucine
zipper, or exon 7 of ZNF384, which retains only the zinc finger and QA-rich domains.
ZNF384-rearrangements occur across all age groups in B-ALL, though only
reported in pediatric cases of MPAL, and are associated with intermediate
prognosis4,26,27. The median age at diagnosis is 14.3, with the peak of incidence in the
adult and young adult (AYA) population where ZNF384 fusions are the driving lesion in
5% of B-ALL tumors4,26,28. The hallmark feature of this subtype of leukemia is the
unique immunophenotype which expresses lymphoid cell-surface markers and aberrant
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Table 1-1.

Summary of ZNF384 fusion partner genes and characteristics.

N terminal partner
EP300
CREBBP
TCF3

TAF15
EWSR1
CTLC
ARID1B
SMARCA2
NIPBL
ATP5C1
BMP2K
SMARCA4
SYNRG
SMARCA2-ZNF362

Exon breakpoint
e6-e3, e6-e2, e11-e3
e4-e3, e5-e3, e6-e2, e6-e3
e11-e2, e11-e3, e13-e2,
e13-e3, e13-e5, e16-e2,
e17-e7, e18-e7
e6-e3, e7-e3, e9-e3, e11-e3
e7-e2, e7-e3, e7-e7, e8-e2,
e11-e3
e21-e3
e4-e4, e5-e4, e9-e3
e4-e3
e9-e2
e4-e3
e14-e3, e15-e3
N/A
e14-e3
N/A

Age
range
3-56
2-64
1-33

Age
median
16
7
4

B-ALL
reports
84
7
49

MPAL
reports
9
1
10

3-74
2-29

16
4

27
7

3
1

10
4-22
11
7
7
5
12
22
15

10
7
11
7
7
5
12
22
15

1
3
1
1
1
1
1
1
1

0
0
0
0
0
0
0
0
0

Notes: The exon breakpoints, patient age, and disease are listed here. B-cell acute
lymphoblastic leukemia (B-ALL); mixed phenotype acute leukemia (MPAL).
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Figure 1-2. ZNF384 and oncogenic fusion proteins in leukemia.
Structure of wild type ZNF384 and all reported ZNF384 fusions with the functional
domains annotated. The most common breakpoint is shown for each, although, there are
multiple reported breakpoints for EP300-ZNF384, CREBBP-ZNF384, TAF15-ZNF384,
EWSR1-ZNF384, TCF3-ZNF384, ARID1B-ZNF384, and BMP2K-ZNF384.
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myeloid markers, to a varying degree. Tumors are CD19 positive, CD10 dim or negative,
often CD33 and/or CD13 positive, and occasionally myeloperoxidase (MPO)
positive16,25,29. MPO positivity is what distinguishes B/myeloid MPAL cases from BALL cases with aberrant myeloid marker expression12. There are no significant
differences in the prevalence of concomitant somatic genetic alterations between
ZNF384-rearranged MPAL and B-ALL16. The cause of MPO expression variability
between patients is unknown, but is likely plastic, and should be consider substandard to
the presence of ZNF384 rearrangements when determining diagnosis, prognosis, and
treatment.
Interestingly, all cases with ZNF384 rearrangements cluster together with a
distinct gene expression profile regardless of their diagnosis (B-ALL or MPAL) or Nterminal fusion partner16. When compared to non-ZNF384-rearranged B-ALL, ZNF384rearranged leukemia has reduced expression of genes related to B-cell development
(VPREB1 and IKZF1), cell cycle, oxidative phosphorylation, and DNA repair29,30. There
is enriched expression of hematopoietic stem and myeloid progenitor signature genes,
JAK/STAT signaling pathway genes, leukocyte adhesion and differentiation genes, and
apoptosis pathway genes29,30. Additionally, when cases are clustered based on gene
expression there are a few cases that cluster in the ZNF384-rearranged group although
they do not have the fusion; these patients are classified as ZNF384-like4,31. There is one
patient classified as ZNF384-like that harbors a SMARCA2-ZNF362 rearrangement
however, the driving lesion in the remaining cases is still unknown32. Thus,
rearrangement of ZNF384, and presumed functionally related genes such as ZNF362,
drive generation of leukemias with similar transcriptional deregulation, although the
mechanism of leukemogenesis has not been defined.
As mentioned previously, chromosomal alterations that define subtypes are often
initiating events that require additional mutations to develop leukemia. Common
concomitant genetic alterations in ZNF384-rearranged leukemia include alterations of
Ras pathway genes (NRAS, KRAS, PTPN11), B-cell regulators (ETV6, IKZF1, PAX5,
VPREB1), and epigenetic genes (KMT2D, SETD2, CREBBP, KDM6A)28,31,33,34,35,36. A
few studies suggest that specific co-lesions are more or less prevalent according to the Nterminal fusion partners, specifically, PTPN11 mutations are prevalent in TCF3-ZNF384
leukemia and CREBBP mutations are absent in cases with EP300 or CREBBP
translocations, suggesting redundancy31,34. Defining fusion partner-specific
characteristics; such as frequency, immunophenotype, common concominant alterations,
average age at diagnosis, and outcome, is challenging because ZNF384-rearranged cases
are relatively low in each cohort and thus far the results are conflicting. The most
frequent fusion partners are EP300 and TCF3; rearrangement with TAF15 is moderately
frequent; and ARID1B, CREBBP, and EWSR1 are rare, though recurrent (Table 1-1).
Rearrangement with ATP5C1, BMP2K, CLTC, NIPBL, SMARCA2, SMARCA4, and
SYNRG have each been reported in only one patient. Overall, ZNF384 fusions occur
across all age groups with a peak in AYA, however, TCF3-ZNF384 is frequently
reported in infants, occurs at a median age of 4, and has never been reported in a patient
over 33 years old. Generally, patients with ZNF384 rearrangements have a good
outcome, however inferior outcomes with TCF3-ZNF384, compared to other ZNF384-
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rearranged patients, has been reported, although, further studies with a greater number of
patients are needed to strengthen this finding27,29,30.

Normal Function of ZNF384
ZNF384 is a ubiquitously expressed transcription factor that was discovered
simultaneously for its interaction with BCAR1 ( also known as p130Cas) at focal
adhesions (ZNF384 was named CIZ, Cas-interacting zinc finger protein) and as a nuclear
matrix transcription factor that couples parathyroid hormone (PTH) signaling to changes
in nuclear organization in osteoblasts (ZNF384 was named NMP4, Nuclear Matrix
Protein 4)37,38. Specifically, Nakamoto et al. found that extrinsic cellular changes, such as
loss of focal adhesions, are relayed from integrins through p130Cas to ZNF384. ZNF384
then shuttles to the nucleus where it binds to an AT-rich consensus sequence and
regulates expression of numerous matrix metalloproteases38. Alvarez et al. were looking
for transcription factors responsible for altering rat type I collagen alpha1 (Col1a1)
promoter geometry in response to changes in cell shape and adhesion upon PTH
treatment. They described ZNF384 as a nuclear matrix architectural transcription factor
that could bind and bend the AT-rich minor groove of the Col1a1 promoter37.
ZNF384 has an N-terminal AT-hook domain which has been shown to interact
with the DNA major groove and is characteristic of architectural transcription factors37.
There are multiple splicing isoforms that encode proteins containing five to eight
Cys2His2 zinc fingers which mediate binding to AT-rich DNA minor grooves39. The
inclusion of particular zinc fingers does not affect binding at the COL1A promoter but
does affect nuclear localization and association with the nuclear matrix39,40. Specifically,
full-length isoforms have diffuse nuclear distribution but the isoform lacking zinc fingers
4 and 5 is isolated to two distinct, non-nucleolar foci in the nucleus40. The C-terminal end
of the protein contains a QA-rich region that acts as a transactivation domain.
Interestingly, the activation driven by this domain is dependent on the presence of
upstream domains and the organization of the regulatory elements surrounding the
consensus sequence39. This suggests that interactions with co-factors play a critical role
in the ability of ZNF384 to regulation transcription.
To investigate the cellular role of ZNF384, two groups independently developed
Zfp384 (the mouse ortholog of ZNF384) knockout mouse models. Neither model
displayed gross morphologic abnormalities although, they did observe variable degrees of
spermatogenic cell degeneration and skewed Mendelian ratios of homozygous knockout
pups, suggesting embryonic lethality41,42. Detailed analysis of the skeleton revealed
significantly enhanced bone mineral density and bone mineral content in both models.
Characterization of the bone marrow showed no differences in hematopoietic cellularity
except a two-fold increase of CD8 positive T cells43. Although ZNF384 is ubiquitously
expressed, the phenotypic changes observed in the knockout mouse models were modest,
possibly due to redundancy with the homolog, ZNF362. However, further stimulation of
the skeletal or immune systems of these mice led to notable discoveries.
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PTH is a treatment for osteoporosis that stimulates osteoblast expansion and bone
formation. In humans, this treatment is successful for roughly two years before bone
formation returns to baseline43. In mice, the anabolic window for PTH treatment is only 3
weeks. However, in Zfp384 null mice this anabolic window was extended and PTH
stimulated new bone formation until the end of the study at seven weeks43. One
mechanism of ZFP384 that contributes to this phenotype is its suppression of Mmp13
expression. Upstream of the Mmp13 promoter is a PTH response region that includes a
ZFP384 binding site and an adjacent RUNX2 binding site44. Through a series of
mutagenesis and transactivation experiments, it was shown that ZFP384 and RUNX2
bind this region as repressive TFs and disruption of binding leads to increased Mmp13
expression in response to PTH treatment. Remarkably, the construct that disrupted both
ZFP384 and RUNX2 binding had an 11-fold increase in expression44. This suggests that
ZFP384, in collaboration with RUNX2, represses Mmp13 expression after prolonged
exposure to PTH. Additionally, knockout mice also had increased bone formation
compared to controls when treated with bone morphogenetic protein-2 (BMP2)45.
A second study utilized administration of K/BxN serum to mice to induce
arthritis. These arthritic mice have elevated levels of ZFP384 in the articular cartilage
which led investigators to examine the effects of K/BxN treatment in the Zfp384
knockout mice. Upon treatment, knockout mice had 50% lower clinical scores, no soft
tissue swelling, reduced cartilage loss, suppressed bone reabsorption, and suppressed
inflammatory cell infiltration compared to wild type mice. Deficient mice had reduced
gene expression of key regulators of arthritis development including two direct targets of
ZFP384, Mmp3 and Il1b46.
Loss of ZFP384 also protects mice against H1N1 influenza A virus infection. The
viral clearance, adaptive immune response, and total monocyte and neutrophil count was
similar between wild type and knockout mice, however, the recruitment of monocytes
and neutrophils to the lungs was reduced in knockout mice which led to less
inflammation and better outcomes. They demonstrated that ZFP384 directly binds and
activates expression of pro-inflammatory cytokines (Il-1b and Il-6) and chemokines
(Ccl2, Ccl7, Cxcl1) which are important for monocyte and neutrophil recruitment after
influenza infection47.
In summary, Zfp384 knockout mice have increased bone formation, decreased
arthritis, and decreased effects of influenza infection compared to WT mice. Each
phenotype can be explained by specific targets of ZFP384 binding that are deregulated in
the knockout mouse. Overexpression of ZNF384 has also been reported as a marker for
metastasis and poor outcome in cancer. In B16 melanoma cells, expression of ZNF384 is
correlated with metastasis to the bone and this relationship was validated experimentally
using constructs to overexpress or knock down ZNF38448. Finally, high expression of
ZNF384 is correlated with tumor recurrence and poor overall survival in patients with
hepatocellular carcinoma. Down regulation of ZNF384 led to lower expression of Cyclin
D1, a direct target of ZNF384, and suppressed cell proliferation49.
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Transactivation experiments have confirmed that ZNF384 regulates expression of
col1a1, mmps, cytokines (Il-1b and Il-6), chemokines (Ccl2, Ccl7, Cxcl1), and Cyclin D1
which play a role in the observed phenotypes of the knockout mouse models38,46,47,49,50.
Comparison of chromatin immunoprecipitation sequencing (ChIP-seq) data for ZNF384
binding in four cell lines (MC3T3-E1 osteoblast-like cells, ES-E14 embryonic stem cell,
MEL B cell lymphoma, and CH12 B cell lymphoma) identified 2114 core target genes
common to all cells. The top two gene ontology (GO) terms enriched in this gene set are
regulation of transcription and chromosome organization51. Furthermore, the ENCODE
ChIP-seq Significance Tool revealed that the core targets of ZNF384 were also target
regions for proteins that regulate chromatin organization and proteins that maintain
stem/progenitor pluripotency/multipotency51. Additionally, this dataset confirmed
ZNF384 binding only at the previously predicted consensus sequence, homopolymeric
(dA dT), with the majority of binding in or near the transcription start site (TSS) or in
intragenic regions51.
Other potential, but less investigated, mechanisms of ZNF384 are its role as a key
regulator of ribosome biogenesis and the unfolded protein response during endoplasmic
reticulum stress through regulation of c-Myc and Gadd34 expression and its role as an
inhibitor of the β-catenin/ERK/Akt/GSK3β pathway in osteoblasts52,53.

Fusion Partners
CREB binding protein (CREBBP, CBP) and E1A-binding protein P300 (EP300)
are homologous proteins that act as acetyltransferases and transcriptional coactivators.
They are well-known for acetylating lysine 18 and 27 of histone 3 (H3K18Ac and
H3K27Ac), which marks active promoters or enhancers. Mouse models have shown that
they have essential, yet distinct, roles in hematopoietic development and maintenance54.
Both CREBBP and EP300 are involved in leukemic transformation by either being
directly mutated, with a unique prevalence of CREBBP mutations at relapse, or through
key interactions with mutant proteins55,56. Additionally, mice transplanted with bone
marrow cells lacking either Crebbp or Ep300 develop hematologic malignancies54.
TATA box-binding protein-associated factor 68 kDA (TAF15) and Ewing
sarcoma (EWSR1) belong to the FET family of transcription factors. This unique class of
proteins is involved in transcription, by directly interacting with DNA and co-factors,
RNA processing, and local translation57. The N-terminal portion of these proteins
contains a disordered domain that, when mutated, aids in development of
neurodegenerative disorders58. Interestingly, this same region is retained in oncogenic
fusion proteins and the C-terminal fusion partner determines the tumor type. FET fusions
most commonly drive sarcomas and leukemia.
Transcription factor 3 (TCF3), formerly known as E2A, is a member of the E
proteins family of basic helix-loop-helix (bHLH) transcription factors. Expression of
TCF3 is essential for normal lymphocyte development and function59. Additionally,
TCF3 is commonly mutated in hematologic malignancies with the most frequent
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alteration being chromosomal translocations that drive up to 5% of B-cell leukemia.4,59.
TCF3-PBX1 and TCF3-HLF are recurrent in B-ALL and although the TCF3 breakpoints
are similar between all three fusions, the C terminal partner leads to markedly different
gene expression profiles4,29,60.
The SWI/SNF chromatin remodeling complex regulates nucleosome positioning
using ATP hydrolysis. This is an elaborate process that utilizes various subunits
depending on the cellular contexts and purposes, with the main objectives being to
regulate transcription and DNA-damage repair61. Genes encoding members of the
SWI/SNF complexes are mutated in >20% of human tumors62. Frequently mutated
subunits include ARID1A and SMARCA4, however their paralogs, ARID1B and
SMARCA2 are rarely mutated63. Interestingly, these subunits, ARID1B and SMARCA2,
along with SMARCA4 have been identified as fusion partners with ZNF384. Recent
studies have begun to reveal the importance of this complex for normal hematopoiesis
and how deregulation, through mutations or interactions with oncoproteins, leads to
leukemia64,65,66.
The fusion partners that have been identified in only one patient each also tend to
have more obscure cellular functions and their relationship to leukemia development is
unclear. ATP5C1 is a subunit of the mitochondrial ATP synthase. Bone morphogenic
protein 2 inducible kinase (BMP2K) is thought to regulate osteoblast differentiation.
NIPBL, named for its homologous protein in Drosophila, plays an important role in
loading the cohesion complex onto chromatin and has recently been implicated in
regulating hematopoietic differentiation and leukemic transformation67,68. Clathrin heavy
chain 1 (CLTC) is a component of the clathrin coat that facilitates vesicle formation.
Similarly, synergin gamma gene (SYNRG) may play a role in clathrin-coated vesicle
trafficking through interactions with the adapter protein complex.
Nearly all key domains (acetyltransferase, DNA binding, RNA binding,
transactivation, helicase, etc.) are lost in these fusion proteins but generally protein
interaction domains remain. Interestingly, this diverse range of partners leads to a very
distinct gene expression profile with no differences in gene expression based on fusion
partner, which suggests that all ZNF384 fusions, in some way, share a mechanism of
transcription deregulation and cellular transformation.

Modeling ZNF384 Rearrangements
A limited number of publications have attempted to elucidate the role of ZNF384
rearrangements in cellular transformation. Overexpression of ZNF384 fusions (TAF15ZNF384, EWSR1-ZNF384, TCF3-ZNF384, SYNRG-ZNF384, or EP300-ZNF384) in
NIH3T3 cells leads to morphological changes and foci formation8,26,69. Two independent
mouse transplantation experiments have shown that expression of EP300-ZNF384 leads
to leukemia development in mice. When primary mouse pro-B cells were transfected
with EP300-ZNF384 and transplanted into NOD/SCID-IL2RG (NSG) mice, mice
developed pre-B ALL with a latency of 230 days26. Moreover, when mouse lineage-
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depleted bone marrow cells were transfected with EP300-ZNF384 and transplanted into
Balb/c mice, latency was reduced to 100 days and tumors were lymphoid deficient, cKit+
acute leukemias32. The difference in lineage and latency is likely due to the cell type that
was transplanted; the pro-B cell is already committed to the lymphoid lineage and not
dividing as quickly as the lineage-depleted bone marrow, which contains stem and
progenitor cells.
Fusion proteins, like wild type ZNF384, localize in the nucleus, outside nucleoli,
and are able to bind the wild type consensus sequence8,32,69. A series of transactivation
experiments have shown that ZNF384 fusions have a varied effect on transcriptional
regulation that may be dependent on co-factor interaction. Specifically, TAF15-ZNF384,
EWSR1-ZNF384, and TCF3-ZNF384 do not activate transcription of MMP7, a target of
wild type ZNF384, however, SYNRG-ZNF384 and EP300-ZNF384 do activate
expression8,26,69. Additionally, it has been shown that ZNF384 fusions are able to activate
transcription of the most highly upregulated genes in ZNF384-rearranged patients,
although, transactivation by the fusions is not always greater than wild type34,70,71. Viral
expression of the fusions in leukemia cell lines; REH, THP-1, and NALM-6, leads to
increased expression of the same target genes in addition to upregulation of stem and
progenitor cell signatures70,71. One mechanism for this upregulation is interaction with
EP300, revealed by GST-pull down of EP300-ZNF384, which leads to enhanced
transcriptional activation71. Conversely, another group suggests that this interaction
causes a dominant negative effect and leads to global loss of histone acetylation which
renders the cells sensitive to histone deacetylase inhibitors34. Overall, some insight into
how ZNF384 fusions lead to cellular transformation has been gained from experiments
published thus far, however, many key questions remain unanswered.
In order to address these questions my project is based on the hypothesis that
ZNF384 rearrangements play a fundamental role in altering the normal stem cell
processes and driving acute leukemia by disrupting gene regulation. The goal was to
model the fusions and co-lesions in vitro and in vivo to investigate the impact on
hematopoiesis and leukemia development. Additionally, to understand how these fusions
disrupt gene expression we used integration of multiple biochemical approaches to
describe global differences in fusion binding compared to wild type binding, acetylation,
chromatin accessibility, and gene expression. We have created a faithful model of human
ZNF384-rearranged leukemia and provided experimental insights to describe the
mechanism that can be used in future studies for the development of targeted
therapeutics.
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CHAPTER 2.

VIRAL APPROACHES TO MODEL ZNF384
REARRANGMENTS

Introduction
Chromosomal rearrangements involving ZNF384 were identified as the defining
lesion in 5% of B-ALL, which included pediatric, young adult, and adult patients 4,28,36.
Additionally, in pediatric ALAL, ZNF384 rearrangements were a subtype-defining lesion
for 43% of B/myeloid leukemias 16. All tumors, whether initially diagnosed as B-ALL or
B-myeloid MPAL express CD19 and are dim for CD10, two markers used for B-ALL
diagnosis. They also have varying expression of myeloid markers CD13, CD33, and
MPO. Expression of MPO by flow cytometry or immunocytochemistry is a key marker
used to distinguish B-ALL from B/myeloid MPAL 1. As there is a spectrum of MPO
expression in ZNF384-rearranged leukemia; ranging from no expression, expression at
the RNA but not protein level (B-ALL), to protein expression in a subset of leukemia
cells or all cells, thus, the distinction into disease subtype based on this marker alone
lacks biological justification.
Accordingly, leukemic samples from B-ALL or B/myeloid MPAL patients with
ZNF384 rearrangements cluster together with a distinct gene expression profile 4,16,29,30.
Upregulated pathways include stem cell pathways, specifically, genes expressed by
normal hematopoietic stem cells (HSC) and granulocyte-macrophage progenitor (GMP)
16,29
. Frequently reported upregulated genes are GATA3, NCOR1, TFP1, SALL4, TDRD9,
DOK5, and FLT3, with downregulation of B-cell pathways16 29. Analysis of gene
expression data from pediatric B-ALL, T-ALL, AML, and ALAL cohorts revealed that
all ZNF384-rearranged patients cluster together regardless of their diagnosis (Figure
2-1A) 16. Furthermore, we compared the gene expression using only ZNF384-rearranged
patients to see if distinctions could be made based on disease entity and found no
clustering (Figure 2-1B). ZNF384 is fused to a diverse range of N-terminal partners,
many of which are involved in chromatin modification and transcriptional regulation.
Thus, there is the possibility that N-terminal portions of the fusions have distinct roles in
cellular transformation. To address this, we compared the gene expression of all ZNF384rearranged tumors and did not observe clusters based on N-terminal partner (Figure
2-1C).
Additionally, we compiled all recurrent genomic alterations in ZNF384rearranged leukemia. Our results agree with previously published reports of high
frequency of Ras pathway mutations, inactivation of ETV6, and deletion of CDKN2A/B
encoding the INK4/ARF tumor suppressors in 38%, 37%, and 18% of cases, respectively
(Figure 2-2) 16,28-31,33. Moreover, comparison of concomitant lesions in ZNF384rearranged B-ALL or B/myeloid MPAL found no differences in lesions, except KDM6A
that was only found in B/myeloid cases 16. However, other genomic studies have reported
KDM6A mutations in ZNF384-rearranged B-ALL 34. We have observed propensity
towards phenotype based on N-terminal partner, with over half of the ZNF384-rearranged
B/myeloid cases harboring TCF3-ZNF384, while this fusion only accounts for 26% of the
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Figure 2-1. ZNF384-rearranged leukemia gene expression profile.
(A) t-distributed stochastic neighbor embedding (t-SNE) plot of top 1,000 variably
expressed genes of ALAL, B-ALL, T-ALL, ETP-ALL, AML, and normal lymphocytes,
showing ZNF384-rearranged cases cluster together. Modified from final submission with
permission. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of
mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373-9.4 (B) t-SNE plot of top
1,000 variably expressed genes of ZNF384-rearranged leukemia annotated by disease (C)
or N-terminal fusion partner. This shows that cases do not cluster based on disease
phenotype, B-ALL or B/M MPAL, or by fusion partner.
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Figure 2-2. ZNF384-rearranged leukemia mutational landscape.
Mutations observed in ZNF384r B-ALL (n = 46) and ZNF384r B/M MPAL (n = 14),
showing similar mutational profile between the two phenotypically defined subtypes.
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ZNF384-rearranged B-ALL cases in this cohort (Figure 2-2). Overall, these observations
indicate that the key genomic alterations driving the pathogenesis of ZNF384-rearranged
leukemia are identical regardless of final lineage.
Thus, collectively, gene expression data, mutational burden, and previous
experiments showing that transplantation of subpopulations of ZNF384-rearranged
patient tumors could repopulate the immunophenotypic diversity in vivo, suggests one
disease entity defined by ZNF384 rearrangements, which transcends immunophenotype. I
aimed to investigate the interplay between ZNF384 fusions, cell of origin, and/or colesions in leukemogenesis and specification of leukemia lineage using in vitro and in vivo
assays. Moreover, as described in detail below, I observed variable usage of ZNF384
exon 8, which encodes the 4th and 5th zinc fingers of the ZNF384 fusion proteins, and I
sought to examine the influence of the presence or absence of this exon in
leukemogenesis.
Specifically, I used colony forming unit assays (CFU) to explore if expression of
the fusions, under myeloid or lymphoid conditions, could alter self-renewal capacity or
lineage output of mouse hematopoietic stem and progenitor cells (HSPCs). This assay is a
staple in the field to measure hematopoietic cell transformation. Additionally, I used
mouse transplantation assays to determine the role of the fusions in leukemogenesis. I
chose to use lentiviral overexpression of the fusions and concomitant lesions as the
approach for these assays because it is a well-used expression model that enabled me to
easily study multiple fusions and co-lesions simultaneously. Also, the expression vector
has an internal ribosomal entry site (ires) followed by a fluorescent protein so infected
cells can be identified by flow cytometry. The immunophenotype was determined in all
experiments using the following panel of mouse pan-hematopoietic markers: B220 is
expressed on lymphocytes; CD19 is expressed on B-cells; CD3 is expressed on T-cells;
Mac1 (also known as CD11b) is expressed on monocytes, macrophages, and
granulocytes; Gr-1 is expressed on myeloid cells, with highest expression on
granulocytes; CD41 is expressed on platelets and megakaryocytes; TER-119 is expressed
on erythrocytes; and CD34 is expressed on hematopoietic stem and progenitor cells.
Using these assays, I examined transformation ability in mouse HSPCs and pre-B
cells, modeled fusions with the co-occurring alterations of ARF-null (model CDKN2A/B
loss) and NRAS G12D, and investigated the differences in exon 8 splicing isoforms.

Methods

Immunoblotting
Cryopreserved patient samples or cell lines were lysed in RIPA buffer (Sigma)
and 30 μg of protein was loaded and run on 4-12% NuPage Bis-Tris gels (Life
Technologies) at 160V for 1 hour. Blots were probed with anti-ZNF384 (Abcam,
Ab176689, 1:1000).
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Lentiviral cloning
RNA isolated from patient samples was used to make cDNA with the Superscript
III First-Strand Synthesis System (Invitrogen). ZNF384 (with or without exon 8), EP300ZNF384 (with the breakpoint of EP300 exon 6 fused in frame to exon 3 of ZNF384),
TAF15-ZNF384 (exon 6 – exon 3), TCF3-ZNF384 (exon 13 – exon 5) (with or without
exon 8), and CREBBP-ZNF384 (exon 6 – exon 3) breakpoints were validated and fulllength transcripts were amplified by PCR using Phusion High-Fidelity DNA Polymerase
(New England Biolabs) and the primers listed in Appendix A Table A-1. Amplified
products were purified using the Wizard SV Gel and PCR Clean-up system (Promega)
and validated by Sanger sequencing. Full-length transcripts were cloned into the pCL20c
MSCV-ires-GFP lentiviral vector. RNA encoding NRAS G12D was amplified, purified,
and cloned into pCL20c-MSCV-ires-mRFP. An in-frame HA (hemagglutinin) epitope tag
was added directly after the start codon (EP300-ZNF384, TAF15-ZNF384) or directly
before the stop codon (ZNF384, TCF3-ZNF384) by mutagenesis using the QuikChange II
XL or NEB Q5 Site-Directed Mutagenesis kit (Agilent). All constructs were verified by
restriction enzyme digestion and Sanger sequencing.

Lentivirus production
HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS); 1X penicillin, streptomycin and Lglutamine (Gibco). Lentivirus was produced by transfecting HEK293T cells with pCAG
RTR, pCAG HIV, and the envelope pHDMG (to infect mouse lineage negative or human
CD34+ cells) or CAG4-Eco (to infect ARF-null mouse pre-B cells) using Fugene HD
(Promega) according to manufacturer’s recommendation. Cell culture medium was
changed 18 hours post transfection. Ecotropic virus production was in DMEM, 10% FBS
and HDMG virus production was in Iscove’s modified Dulbecco’s medium (IMDM),
10%FBS. Viral supernatant was collected and filtered 42 hours and 66 hours after
transfection. Lentivirus with the pHDMG envelope was concentrated 100-fold by
ultracentrifugation at 100,000XG for 90 minutes. Virus was titered by transduction of
NIH3T3 cells followed by flow cytometry to measure the proportion of GFP or mRFP
positive cells and used fresh for transduction of hematopoietic cells.

Mouse colony forming unit assay
Bone marrow cells were harvested from 6-8 week old wild type C57BL/6 mice
(Jackson Laboratory), and lineage negative HSPCs were isolated using the EasySep
Mouse Hematopoietic Progenitor Cell Isolation Kit (StemCell Technologies) according
to the manufacturer’s recommendation. HSPCs were cultured for 48 hours in IMDM with
20% FBS supplemented with recombinant mouse stem cell factor (SCF; 50 ng/mL), FLT3 ligand (40 ng/mL), IL-6 (30 ng/mL), IL-3 (20 ng/mL), and IL-7 (10 ng/mL) (Peprotech). Cells and viral supernatants (pCL20c MSCV-ires-GFP lentivirus expressing the
WT or fusion genes of interest) were added to RetroNectin-coated plates (Takara) and
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centrifuged at 1500XG for 90 minutes at room temperature. Cells were maintained at
37°C for 48 hours and transduced GFP positive cells were obtained via fluorescenceactivated cell sorting. For clonogenic assays, 10,000 cells were plated in triplicate in
Methocult M3231 (StemCell Technologies) with the appropriate factors (SCF,
100 ng/mL; FLT-3 ligand, 10 ng/mL; IL-7, 20 ng/mL) for mouse lymphoid progenitor
cells or in M3534 (StemCell Technologies) with the addition of GM-CSF (10 ng/mL) for
mouse myeloid progenitor cells. Colonies were scored 7–10 days later. For replating,
1x104 cells were cultured in identical conditions, with colonies counted between days 710. Colony identity was confirmed via morphological analysis of Wright-Giemsa stained
cytospin preparations and by flow cytometric analysis of a panel of lineage markers:
B220-Alexa700 (eBioscience, 56-0452-82, RA3-6B2, 1:100); Gr1-BV711 (Biolegend,
108443, RB6-8C5, 1:100); Ter119-APC-Cy7 (BD Bioscience, 560509, TERR-119,
1:200); CD3-APC (BD Bioscience, 553066, 145-2C11, 1:100); Mac1-BV605 (Biolegend,
101237, M1/70, 1:50); CD41-BUV396 (BD Bioscience, 564056, MWReg30, 1:100);
CD34-BV421 (BD Bioscience, 562608, RAM34, 1:100) and CD19-PE-Cy7 (BD
Bioscience, 552854, 1D3, 1:100).

Mouse transplantation
Mice were housed in the American Association for Accreditation of Laboratory
Animal Care–accredited facility of St Jude Children’s Research Hospital. All
experiments were approved and were in compliance with the SJCRH Institutional Animal
Care and Use Committee. To acquire donor cells, 6-8 week old C57BL/6 mice or ARFnull mice were pretreated with 5-fluorouracil at 150mg/kg by intraperitoneal injections
and bone marrow cells were harvested 5 days later72. Cells were treated with RBC Lysis
Buffer (BioLegend) according to the manufacturer’s recommendation. Cells were
maintained in IMDM with 20% FBS supplemented with recombinant mouse SCF
(50ng/mL), FLT-3 ligand (50ng/mL), IL-3 (10ng/mL), IL-6 (10ng/mL), IL-7 (10ng/mL)
(PeproTech). Cells were added to non-tissue culture treated plates that were prepared
with RetroNectin (Takara). Viral supernatant (pCL20c MSCV-ires-GFP lentivirus
expressing the WT or fusion genes of interest or pCL20-NRAS G12D-ires-RFP) was
added to the wells and the plates were centrifuged at 1500XG for 90 minutes at room
temperature. Cells were collected 24 hours later and 2 x 105 cells were transplanted by
tail vein injection into lethally irradiated (1100 Rad) 8-12 week old C57BL/6 mice. A
portion of cells were retained in culture and the proportion of GFP positive or GFP, RFP
double positive cells was determined by flow cytometry 48-72 hours post-transduction.
Animals that became moribund were euthanized and blood, bone marrow, and spleen
were analyzed for evidence of leukemia, using morphology, flow cytometry and
histopathologic analysis. Post-mortem immunophenotyping of bone marrow and spleen
cells was performed on the GFP positive or GFP, RFP double positive cells to determine
the lineage of disease in engrafted samples using the following panel of antibodies:
B220-BV605 (Biolegend, 103244, clone RA3-6B2, 1:20); Gr1-PerCP-Cy5.5 (BD
Biosciences, 552093, clone RB6-8C5, 1:50); Ter119-V500 (BD Biosciences, 562120,
clone TER-119, 1:50); CD3-APC (BD Biosciences, 553066, clone 145-2C11, 1:50);
Mac1-Alexa700 (BD Biosciences, 557960, clone M1/70, 1:50); CD41-BUV396 (BD
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Bioscience, 564056, MWReg30, 1:100); and CD19-APC-Cy7 (BD Biosciences, 552854,
clone 1D3, 1:50). For secondary transplantation, sub lethally irradiated (550 Rad) 8-12
week old C57BL/6 mice were injected with 5 x 105 fluorescence-activated cells sorted,
GFP positive or GFP, RFP double positive bone marrow cells from the primary leukemic
mice. The same monitoring, euthanasia, and tissue analysis was used for secondary
transplant recipients.

Pre-B cell culture
Mouse ARF-null pre-B cell cultures were established as described 73,74. Cells and
viral supernatants (pCL20c MSCV-ires-GFP lentivirus expressing the WT or fusion
genes of interest or pCL20-NRAS G12D-ires-RFP) were added to RetroNectin-coated
plates (Takara) and centrifuged at 1500XG for 90 minutes at room temperature. Cells
were maintained at 37°C for 48 hours and transduced GFP positive or GFP, RFP double
positive cells were obtained via fluorescence-activated cell sorting. All ARF-null pre-B
cell cultures were grown at 37°C with 8% CO2 and maintained in Roswell Park Memorial
Institute medium (RPMI 1640) supplemented with 1X penicillin, streptomycin, Lglutamine; IL-7 (10 ng/mL) (Peprotech); and 55 μM β-mercaptoethanol. 5 x 105 cells
were transplanted by tail vein injection into sub lethally irradiated (550 Rad) 8-12 week
old C57BL/6 mice and monitored for disease development. Animals that became
moribund were euthanized, tissue harvested and analyzed as described above.

RNA-sequencing
RNA was extracted from 2-5 x 106 sorted tumor cells using AllPrep DNA/RNA
Mini Kit (Qiagen). Transcriptome sequencing (RNA-sequencing) was performed using
the TruSeq library preparation on the Illumina HiSeq 2000 platform as previously
described75. Sequencing was paired end and performed using total RNA and stranded
RNA-sequencing (n = 32). Paired-end reads from RNA-seq were aligned to mm10
reference genome and final BAM files were constructed.

RNA-sequencing analysis
Major hematopoietic cell types in the mouse models were investigated using
xCell, a webtool that performs cell type enrichment analysis from gene expression data
for 64 immune and stroma cell types76. Relative enrichment score (Z-score) was
displayed in the heatmap. Read counts from RNA-seq data were imported to DESeq2 R
package for differential gene expression analysis. To perform gene set enrichment
analysis (GSEA), all the genes were ranked according to the fold-change and significance
from differential analysis. GSEA was performed using mSigDB C2 genes and curated
gene sets from in-house analyses.
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Whole-exome sequencing
DNA was extracted from 2-5 x 106 sorted tumor cells using the AllPrep
DNA/RNA Mini Kit (Qiagen). DNA was quantified and checked for quality control and
libraries were constructed, checked for quality control and sequenced as previously
described 77. Briefly, construction utilized DNA tagmentation (fragmentation and adapter
attachment) performed with the reagent provided in the Illumina Nextera rapid exome kit
and was performed using the Caliper Biosciences Sciclone G3 (PerkinElmer). First-round
PCR (ten cycles) was performed using Illumina Nextera kit reagents and clean-up steps
using AMPure XP beads (Beckman Coulter Genomics/Agencourt). Target capture
utilized Illumina Nextera Rapid Capture Expanded Exome and supplied hybridization
and associated reagents. The pre-hybridization pool size was 12 samples, and secondround PCR (ten cycles) was performed with Nextera kit reagents.

Whole-exome sequencing analysis
Whole exome sequencing was performed with 100bp paired end setting. The
paired-end sequencing reads were mapped to mouse genome mm10 using BWA mem
(version 0.7.17). Read sorting based on chromosome position and PCR duplication
marking was performed using Picard (http://broadinstitute.github.io/picard/, version
2.9.4). Then the reads were realigned around potential indel regions by GATK (version
3.7) IndelRealigner module. Sequencing depth and coverage was assessed based on
coding regions (~34Mb) defined by RefSeq genes, with median value of 82% of 100x
coding exon coverage (Appendix A Table A-2). UnifiedGenotyper (within GATK v3.7)
module was applied to call SNVs and Indels from leukemia and paired samples. Variant
annotation against RefSeq gene was done using ANNOVAR 78.

Statistical analysis
Data analyses were performed using Prism version 8.4.3 (GraphPad). Data are
presented as means ± SD. Significance was determined using Student's t test. KaplanMeier analysis and the Mantel-Cox log-rank test were used for survival data.
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Results

Validation of ZNF384 fusion expression in patient samples
I confirmed fusion expression in patient samples by RT-PCR and western blot
when material was available (Figure 2-3A, B). During the cloning process, I observed a
high frequency of alternative splicing isoforms and validated this by analysis of the
RNA-seq data. Exon 8 of ZNF384 is frequently excluded in the fusion transcript, with
inclusion of exon 8 making up 10% of the reads, on average, in patient samples (Figure
2-3C). Interestingly, exon 8 is included in TCF3-ZNF384 fusions in 20% of the reads, on
average with usage higher in MPAL cases compared to B-ALL cases (Figure 2-3C).
Exon 8 encodes 2 of the 5-8 zinc fingers and is likely important for DNA binding
specificity.

Cellular transformation driven by ZNF384 fusions
To determine the effect of ZNF384 fusions on self-renewal, wild type ZNF384
and representative ZNF384 fusions, including exon 8 splicing isoforms, were lentivirally
expressed in mouse HSPCs (Figure 2-4A). When grown in myeloid differentiation
conditions which includes SCF, IL-3, IL-6, and GM-CSF; TAF15-ZNF384, EP300ZNF384, and CREBBP-ZNF384 expressing cells were able to sustain serial replating
(Figure 2-4B). EP300-ZNF384 expressing cells were able to replate for seven rounds and
the immunophenotype, though expressed some myeloid markers, remained immature as
shown by higher expression of CD34 compared to wild type cells (Figure 2-4C, D). In
contrast, TCF3-ZNF384 expressing cells had an initially high colony forming ability but
then were not able to replate after the second round (Figure 2-4B). These cells exhibited
high expression of Mac1 and Gr1, indicating they were myeloid progenitors (Figure
2-4E). In lymphoid growth conditions which includes SCF, Flt3L, and IL-7; only
CREBBP-ZNF384 was able to replate beyond the first round (Figure 2-4F).

Modelling the cooperation of ZNF384-rearrangements and NRAS G12D
To investigate the leukemic potential of ZNF384 fusions, mouse HSPCs were
harvested, transduced, and transplanted without purification of transduced cells prior to
transplantation into recipient mice (Figure 2-4A). Cells expressing empty vector or wild
type ZNF384 were able to engraft with normal lineage outputs, however, cells expressing
ZNF384 fusions had an engraftment disadvantage and mice had no fusion-expressing
cells in their peripheral blood or bone marrow, indicated by lack of GFP expression. I
then co-expressed the fusions with NRAS G12D and repeated the experiment. Cells
expressing TCF3-ZNF384 and NRAS G12D produced an aggressive leukemia with a
mean latency of 82 days (Figure 2-5A). Mice had elevated blood leukocyte counts and
splenomegaly (Figure 2-5B). Leukemia cells expressed MPO, Mac1, and Gr1, but were
negative for CD19, CD3, and Ter119 (Figure 2-5C, D). Although the primary tumors
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Figure 2-3. Validation of ZNF384 fusion expression in patient material.
(A) Validation of expression of ZNF384 fusion transcripts from a subset of patient
samples. RT-PCR reactions from each patient amplified the fusion-specific breakpoint
(BP) and an ACTIN control region (Ctrl) (left panel). Samples were validated by Sanger
sequencing, a representative electropherogram of the CREBBP-ZNF384 fusion
breakpoint is shown here (right panel). (B) Samples analyzed for fusion expression by
immunoblotting include: HEK293T cells transduced with Empty Vector, CREBBPZNF384 (kDa 120), EP300-ZNF384 (kDa 120), or TCF3-ZNF384 (kDa 78) and
corresponding patient leukemia cells. Wild type ZNF384 (kDa 65) is endogenously
expressed in all samples. (C) Relative abundance of ZNF384 spicing transcripts in
ZNF384-rearranged B-ALL (dim) and MPAL (bold). Each column represents a case and
shows the cumulative abundance of all isoforms as a proportion within each case. The
average inclusion of exon 8 based on N-terminal partner is marked by the horizontal line
across cases including that partner. TCF3-ZNF384 fusions and MPAL diagnosis are
associated with higher average exon 8 inclusion rate.
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Figure 2-4. Colony forming assay in lineage negative bone marrow cells.
(A) The workflow for colony forming assays and transplantation assays. Bone marrow
was isolated from mice, enriched for HSPC, transduced with representative fusions, and
sorted for colony forming assays (CFU) or transplanted directly into mice. (B) CFU of
lineage negative bone marrow cells expressing wild type or fusions, with or without exon
8, grown in myeloid differentiation conditions. Columns show means of three replicates ±
SD. (C) Cells harvested from CFU after two or more replatings were subjected to flow
cytometry and representative immunophenotype is shown of wild type cells, (D) EP300ZNF384 expressing cells, (E) or TCF3-ZNF384 expressing cells. (F) CFU of lineage
negative bone marrow cells expressing wild type or fusions, with or without exon 8,
grown in lymphoid differentiation conditions. Columns show means of three replicates ±
SD.
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Figure 2-5. Leukemia development in mice transplanted with mouse HSPCs
expressing TCF3-ZNF384 and NRAS G12D.
(A) Survival curves in primary, secondary, and tertiary recipients. Two-sided log-rank
Mantel-Cox test, **P = 0.008 (B) White blood cell (WBC) count (left panel) and spleen
weight (right panel) at death in mice transplanted with indicated cells. The mean
expression is shown by the horizontal line in the scatter dot plot and the error bars
represent the SD. **** p<0.0001. NS, not significant. (C) Haematoxylin and eosin
staining (left panel) and MPO staining (middle panel) of sternal section and bone marrow
cytospin (right panel) of a representative recipient mouse transplanted with cells
expressing TCF3-ZNF384 and NRAS G12D. (D) Immunophenotyping from a
representative mouse showing tumors express Mac1 and Gr1.
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exhibited multi-organ dissemination, with extensive infiltration of bone marrow and
spleen, secondary tumors generally did not engraft. The 10% of tumors that could engraft
secondary and tertiary recipients created phenotypically identical tumors with a slightly
reduced latency (Figure 2-5A). Repeating the same experiment with EP300-ZNF384 or
TAF15-ZNF384 yielded similar clinical characteristics and immunophenotype (Figure
2-6A-D). Tumors expressing EP300-ZNF384 with NRAS G12D were serially
transplantable.
One tumor developed from mice transplanted with cells expressing ZNF384
fusion alone; of the 5 independent experiments transplanting EP300-ZNF384 only
(n=11), TAF15-ZNF384 only (n=4), or TCF3-ZNF384 only (n=14). This tumor was
driven by EP300-ZNF384 expression and had similar clinical features as the tumors
expressing fusion with NRAS G12D (Figure 2-6A, B, E). The latency of this tumor was
125 days and the immunophenotype differed from the other tumors because it had lower
Gr1 expression (Figure 2-6A, F). This tumor was serially transplantable with increased
lymphoid marker expression and reduced latency in each passage (Figure 2-6G).
Notably, EP300-ZNF384 leukemia is more commonly diagnosed as B-ALL versus
B/myeloid MPAL and these results suggest that expression of this fusion encourages a
stronger B-cell phenotype. However, the lack of NRAS G12D in this tumor could also
contribute to the unique immunophenotype.
Mice transplanted with cells expressing NRAS G12D alone also developed
hematopoietic malignancies but had a longer average latency of 113 days and lineage
variability compared to the ZNF384 fusion with NRAS G12D tumors (Figures 2-5A and
2-6A). Tumors analyzed included mast cell leukemias, T-ALLs, and lymphomas. Table
2-1 summarizes all lentiviral transplantation experiments. Together these experiments
revealed that ZNF384 fusions alone have an engraftment disadvantage, but when coexpressed with NRAS G12D, drive AML. Although NRAS G12D is needed for
leukemogenesis in this model, expression of the fusions controls the lineage output.

The effect of TCF3-ZNF384 splicing isoforms
Based on the observation that tumors with ZNF384 fusions predominantly express
the splicing isoform that lacks exon 8 of ZNF384, I wanted to investigate the functional
role of this exon. It has been reported that ZNF384 has multiple splicing isoforms that
produce proteins with 5-8 zinc finger domains 38,50. The isoform lacking exon 8 leads to
an in-frame protein lacking zinc fingers 4 and 5, which have 90% and 81% homology to
zinc fingers 2 and 3, respectively (Figure 2-7A) 39. Localization experiments of ZNF384
splicing isoforms in osteoblast cell lines revealed that the full-length protein had diffuse
distribution in the nucleus while the isoform lacking zinc fingers 4 and 5 localized to two
distinct domains within the nucleus 40. Although, it has been shown that the isoform
lacking zinc fingers 4 and 5 can bind the COL1A1 and MPP7 promoters to activate
expression, formal comparison of DNA binding of these isoforms has not been
performed39.
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Figure 2-6. Leukemia development in mice transplanted with mouse HSPCs
expressing EP300-ZNF384, TAF15-ZNF384, and/or NRAS G12D.
(A) Survival curves in primary recipients transplanted with indicated cells. (B) White
blood cell (WBC) count (left panel) and spleen weight (right panel) at death in mice
transplanted with indicated cells. The mean expression is shown by the horizontal line in
the scatter dot plot and the error bars represent the SD. (C) Immunophenotyping from a
representative ZNF384 fusion with NRAS G12D mouse showing tumors express Gr1
with variable expression of Mac1. (D) Haematoxylin and eosin staining (left panel) and
MPO staining (right panel) of sternal section. (E) Haematoxylin and eosin staining (left
panel) and MPO staining (right panel) of EP300-ZNF384 mouse spleen section. (F)
Immunophenotyping from EP300-ZNF384 mouse showing tumor expresses Mac1 with
some Gr1. (G) Immunophenotyping from EP300-ZNF384 secondary mouse showing
tumor expresses Mac1, Gr1, and dim for CD19.
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Table 2-1.

Summary of mouse lentiviral transplantation experiments.

Experiment Donor Lentivirus
KD018
BL/6 Empty Vector
ZNF384
NRAS G12D
TCF3-ZNF384 -e8
TCZ & NRAS
KD019
BL/6 NRAS G12D
TCF3-ZNF384 +e8
TCZ +e8 & NRAS
KD022
BL/6 NRAS G12D
TCZ +e8 & NRAS
TCZ -e8 & NRAS
KD025
BL/6 Empty Vector
NRAS G12D
EP300-ZNF384
EZ & NRAS
KD027
BL/6 NRAS G12D
TAF15-ZNF384
TAZ & NRAS
KD023
ARF- Empty Vector
null
NRAS G12D
TCF3-ZNF384 -e8
TCF3-ZNF384 +e8
TCZ -e8 & NRAS
TCZ +e8 & NRAS

Mean
n survival Diagnosis
2
n/a
2
n/a
6
135
Mast cell tumor, T-cell leukemia
8
n/a
6
82
Myeloid leukemia, Mast cell neoplasm
2
CD3+ Lymphoma
6
n/a
5
22
Myeloid and monocytic leukemia
4
68
8
48
MPO+ myeloid leukemia
8
23
MPO+ myeloid leukemia
3
n/a
3
90
6
125*
MPO+ myeloid leukemia
6
78
MPO+ myeloid leukemia
6
69
4
n/a
5
70
Histiocytic sarcoma
2
n/a
3
50
CD3+ Lymphoma
5
n/a
5
n/a
7
31
MPO+ myelomonocytic leukemia
7
28
MPO+ myeloid leukemia

n = number of mice in each experimental group
2 ̊ = number of tumors that engraft secondary receipts/ number of secondary transplants attempted

* only one mouse in survival statistics
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2̊

1/3

0/4
0/1
0/1

1/1
1/1

0/1

1/2
0/2

Figure 2-7. TCF3-ZNF384 alternative splicing isoforms.
(A) A schematic representation of TCF3-ZNF384 mRNA splicing isoforms that differ in
exon 8 inclusion. (B) Survival curves in primary recipients transplanted with indicated
cells. Two-sided log-rank Mantel-Cox test, ****P < 0.0001 (C) White blood cell (WBC)
count at death in mice transplanted with indicated cells. The mean expression is shown
by the horizontal line in the scatter dot plot and the error bars represent the SD.
*P=0.0315 (D) Percent of cells expressing Gr1 as determined by flow analysis. The mean
expression is shown by the horizontal line in the scatter dot plot and the error bars
represent the SD. **P=0.0042.
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TCF3-ZNF384 had the highest usage of exon 8 in patient samples, therefore, I
used this fusion to compare isoforms in functional studies (Figure 2-3C). Mouse HSPCs
were harvested, lentivirally transduced with NRAS G12D and TCF3-ZNF384 with exon
8 or without exon 8, and transplanted into recipient mice. Expression of the fusion
isoform with exon 8 led to MPO positive AML with a significantly longer average
latency (Figure 2-7B). Additionally, the blood leukocyte count was lower in the mice
expressing exon 8 (Figure 2-7C). Pathological analysis of the tissue did not reveal any
differences in disease based on TCF3-ZNF384 isoform, however, the immunophenotype
showed higher Gr1 expression in tumors with exon 8 (Figure 2-7D).

Modelling the cooperation of ARF loss, ZNF384-rearrangements, and NRAS G12D
Patients with ZNF384 rearrangements often have chromosomal loss of
CDKN2A/B that encode the INK4A, INK4B and ARF tumor suppressors and cell cycle
regulators. The importance of ARF, specifically, in the pathogenesis of ALL has been
documented using the ARF-null mouse 73,79. To model this concomitant lesion, I used the
ARF-null mouse to harvest HSPCs, transduced these cells, and transplanted them into
recipient mice. ARF-null, TCF3-ZNF384, NRAS G12D tumors were of myeloid lineage
with similar blood leukocyte counts, spleen weights, and immunophenotype to ARF wild
type tumors, however, the mean latency of 29 days was substantially shorter than the 82
days seen in TCF3-ZNF384, NRAS G12D tumors (Figure 2-8A through E, Table 2-1).
Tumors arising from ARF-null, NRAS G12D cells were CD3 positive thymic lymphomas
and B cell lymphomas with an average latency of 50 days (Table 2-1). Only one ARFnull, TCF3-ZNF384, NRAS G12D tumors was able to engraft secondary recipients.

Genomic characterization of ZNF384-rearranged mouse tumors
Whole exome sequencing (WES) of representative tumors from each experiment
revealed no secondary lesions that were predicted to contribute to tumorigenesis and no
large structural variations were identified (Supplemental Data for Chapter 2).
However, one ARF-null, TCF3-ZNF384, NRAS G12D tumor that was able to engraft
secondary recipients acquired a T3557A nonsense mutation in KDM6A (Supplemental
Data for Chapter 2). This gene is recurrently mutated in patients with ZNF384
rearrangements. Overall, this suggests that secondary genomic lesions are not required
for leukemogenesis and the tumors reported are driven by the lesions modelled.
RNA sequencing of all HPSC transplantation-derived tumors followed by
unsupervised hierarchical clustering using the top 1000 differentially expressed genes
revealed two clusters; ZNF384 fusion expressing tumors and non-fusion tumors or
untransduced control cells (Figure 2-9A). Furthermore, xCell analysis, a gene signaturebased method that can determine cell-type enrichment based on the transcriptome, further
characterized the expression signatures of these samples (Figure 2-9B). Fusion tumors
have an enriched expression of HSC, basophil, immature dendritic cell (DC), T helper
cell (Th2), and CMP signatures which are mostly in the myeloid arm of hematopoiesis.
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Figure 2-8. Leukemia development in mice transplanted with ARF-null mouse
HSPCs expressing TCF3-ZNF384 and NRAS G12D.
(A) Survival curves in primary recipients transplanted with indicated cells. (B) White
blood cell (WBC) count at death in mice transplanted with indicated cells. The mean
expression is shown by the horizontal line in the scatter dot plot and the error bars
represent the SD. (C) Spleen weight at death in mice transplanted with indicated cells.
The mean expression is shown by the horizontal line in the scatter dot plot and the error
bars represent the SD. (D) Immunophenotyping from a representative mouse showing
tumors express Mac1 and Gr1. (E) Haematoxylin and eosin staining (left panel), MPO
staining (left, middle panel), RFP staining (right, middle panel), and GFP staining (right
panel) of spleen section.

33

Figure 2-9. RNA expression of ZNF384-rearrangement driven mouse tumors.
(A) Unsupervised hierarchical clustering of tumors generated in mice. (B) Unsupervised
hierarchical clustering xCell analysis showing hematopoietic cell-type signature
enrichment. (C) GSEA showing enrichment of genes that are differentially expressed in
ZNF384-rearranged mouse tumors compared to the GEP of ZNF384r versus nonrearranged patient leukemia. Down-regulated genes in the model are also down-regulated
in patients. (D) A volcano plot displaying -log10pvalue by logFold change to compare
gene expression of tumors driven by TCF3-ZNF384 with exon 8 to TCF3-ZNF384
without exon 8.
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They have repressed expression of most lymphoid and erythroid cell signatures.
Interestingly, the tumors expressing EP300-ZNF384 have a higher enrichment for pro-B
cell, MSC, and myocyte signatures and lower monocyte signature compared to other
ZNF384 tumors. Control cells have low expression of the signatures upregulated in the
tumors, with the exception of immature DC, suggesting they are beginning to
differentiate. Control cells are neutral for expression of most lineages. Non-fusion tumors
have enriched expression of lymphoid (B-cell or T-cell) signatures.
Gene sets of the top upregulated and downregulated genes in the mouse ZNF384rearranged tumors compared to untransduced cells were used to perform gene set
enrichment analysis (GSEA), in which enrichment of these gene sets in the gene
expression signature of human ZNF384r v. non-ZNF384-r leukemia was performed. The
gene set of those genes downregulated in ZNF384 fusion-transduced cells was negatively
enriched in the signature of human ZNF384r leukemia, (Figure 2-9C). However, the
same trend was not observed for upregulated genes (Figure 2-9C). Differential gene
expression analysis comparing mouse leukemias induced by concomitant expression of
TCF3-ZNF384 with retention of exon 8 and NRAS G12D to those tumors induced by
TCF3-ZNF384 lacking exon 8 and NRAS G12D tumors from the same transplantation
experiment revealed key differentially expressed genes (Figure 2-9D). Specifically,
downregulation of immune response genes in TCF3-ZNF384 with exon 8 tumors and
upregulation of cell cycle arrest and anti-proliferative pathways. One of the top
upregulated genes in with exon 8 tumors was Kit, which is a marker of stem cells and
important receptor for cytokine signaling. Interestingly, the top upregulated gene was
Mpo, the marker used to diagnose ALAL.

The effect of ZNF384 rearrangements in ARF-null pre-B cell leukemia
Furthermore, in an effort to model the B-cell phenotype observed in patients, I
lentivirally expressed ZNF384 fusions in ARF-null pre-B cells (Figure 2-10A). In vitro,
expression of the fusions did not transform the cells immunophenotype, proliferation,
cytokine independence, or cell cycle (data not shown). When these cells were
transplanted into recipient mice, there were no differences in survival or clinical
characteristics of mice transplanted with cells expressing empty vector, ZNF384, or
ZNF384 fusions with or without NRAS G12D expression (Figure 2-10B through E).
Additionally, the immunophenotype was not altered by expression of ZNF384 fusions; all
tumors were B-ALL (Figure 2-10F).

Discussion
In vitro mouse HSPC assays have shown that all ZNF384 fusions affect
hematopoietic differentiation, although there is variability in the lineage output and effect
on self-renewal. Interestingly, although CREBBP and EP300 are homologous proteins
with identical breakpoints in the fusions, the ZNF384 fusions containing these partners
had different effects on self-renewal and immunophenotype. It has been reported that
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Figure 2-10. Leukemia development in mice transplanted with ARF-null pre-B
cells expressing ZNF384 fusions and/or NRAS G12D.
(A) The workflow for transplantation assays. ARF-null pre-B cells transduced with
empty vector, wild type, or representative fusions were transplanted directly into mice or
transduced with NRAS G12D and then transplanted into mice. (B) Survival curves in
primary recipients transplanted with indicated cells. Tumors arose from ARF-null pre-B
cells and the expression of fusions did not reduce the latency. (C) Survival curves in
primary recipients transplanted with indicated cells. (D) Spleen weight at death in mice
transplanted with indicated cells. The mean expression is shown by the horizontal line in
the scatter dot plot and the error bars represent the SD. (E) White blood cell (WBC) count
at death in mice transplanted with indicated cells. The mean expression is shown by the
horizontal line in the scatter dot plot and the error bars represent the SD. (F)
Immunophenotype, determined by flow. Columns show means of three replicates ± SD.
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these partner proteins have different roles in hematopoiesis, with CREBBP crucial for
HSC self-renewal and EP300 needed for proper differentiation 54. It is also surprising that
the rarest fusion tested, CREBBP-ZNF384, had the greatest effect in lymphoid
conditions.
The transplantation experiments showed the critical role of concomitant lesions
and cell of origin for ZNF384-rearranged leukemogenesis. Mice transplanted with fusionexpressing HSPCs or ARF-null, fusion expressing cells without NRAS G12D did not
develop leukemia, with one exception. Unfortunately, because the fusion-expressing cells
did not engraft well I could not characterize the effect on cellular transformation in vivo.
These transplantation models required the co-expression of ZNF384 fusions with NRAS
G12D, which led to MPO+ myeloid leukemia with average latency dependent on fusion
partner. I attempted to generate a lymphoid phenotype by using ARF-null donor bone
marrow, which has been shown to promote lymphoid tumors in a BCR-ABL1 transplant
model that typically results in myeloid leukemia 73,80. However, the co-modeling of ARFnull, TCF3-ZNF384, NRAS G12D still led to MPO+ myeloid leukemia. The ARF-null
mouse has only lost expression of one of the proteins encoded by the Cdkn2a/b loci thus
a triple knockout could better recapitulate the lesion identified in patients and possibly
lead to different transplantation results. Additionally, expressing the other ZNF384
fusions with ARF-null and NRAS G12D would perhaps produce a different phenotype.
Similar transplant experiments were performed and reported in the literature.
Specifically, retroviral expression of EP300-ZNF384 in lineage negative, cKitlow cells led
to myeloid leukemia when transplanted into Balb/c mice 32. In my experiments, I did not
observe reproducible leukemia development from the expression of EP300-ZNF384
alone. To duplicate the reported findings, I performed experiments using the methods
described by Liu et al. and no tumors arose. Another transplantation experiment
retrovirally expressed EP300-ZNF384 in mouse pro-B cells and transplanted into
immunocompromised mice 26. They report B-ALL with a median latency of 230 days 26.
ZNF384-rearranged mouse tumors cluster together based on gene expression
analysis with a strong enrichment of HSC signature genes. It appears that they are primed
for myeloid differentiation because of the enrichment of myeloid progenitor and mature
cell signatures while lymphoid signatures are repressed. Although modelling and
analyzing mouse tumors can be technically challenging, I showed that genes
downregulated in our mouse tumors are enriched for genes that are down regulated in
human ZNF384-rearranged leukemia.
This work shows for the first time that ZNF384 fusions have alternative splicing
of exon 8 and that fusion partners differ in frequency of isoform usage. Surprisingly, the
TCF3-ZNF384 splicing isoforms had different latency and clinical features in
transplantation assays. Differential gene analysis revealed increased expression of the
stem-cell gene, Kit, along with other anti-cell cycle and anti-proliferative genes in exon 8
expressing tumors. Additionally, immune response genes were down-regulated. The
longer latency and differentially expressed pathways suggest that the TCF3-ZNF384
splicing isoform with exon 8 activates a more quiescent, stem-cell phenotype than the
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isoform lacking exon 8. Moreover, the top differentially expressed gene was Mpo, which
is upregulated in mouse tumors that express TCF3-ZNF384 with exon 8. Follow-up
experiments plan to investigate if the isoform with exon 8 can bind to Mpo and regulate
expression. This has important clinical implications because MPO is used to distinguish
ZNF384-rearranged B-ALL from B/myeloid MPAL, which leads to different treatment
protocols. It has been suggested regarding ZNF384-rearranged leukemia, and more
recently other subtypes of leukemia, that genomics should supersede immunophenotype.
If Mpo expression is controlled by fusion isoform expression, that adds to the growing
evidence that MPO is an outdated diagnostic marker for ZNF384-rearranged leukemia.
Many subtypes of B-ALL are thought to arise from mutations acquired during an
early stage of B-cell development, such as the pre-B stage, when the cell is committed
but immature. One possible explanation for the phenotype of ZNF384-rearranged
leukemia, B-ALL with aberrant myeloid marker expression, is that the fusion happens in
an early B-cell and can activate myeloid gene expression. Although this is unlikely
considering the cell of origin evidence summarized in Chapter I 16. I have shown that
expressing ZNF384 fusions in ARF-null pre-B cells does not transform the cells. This,
along with the transformation shown in HSPCs, supports that the cell of origin for
ZNF384-rearranged leukemia is an early stem or progenitor cell. Furthermore, in the
following chapters I will provide insight into how ZNF384 fusion expression alters
normal hematopoiesis using alternative experimental approaches.
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CHAPTER 3.

USING GENETICALLY ENGINERRED MOUSE MODELS TO
INVESTIGATE ZNF384 REARRANGEMENTS

Introduction
One challenge of modeling human leukemia is accurately representing the genetic
changes seen in patients. It is important to consider the context of gene expression,
specifically, the appropriate timing, level of expression, and cell type. ZNF384
rearrangements bring two chromosomes together to form a novel fusion gene while
simultaneously disrupting one allele of each gene. The lentiviral models do not capture
this loss of one wild type copy of each gene which could have a functional consequence.
Additionally, the expression of the fusion in patients is regulated by the promoter of the
5’ gene which appropriately regulates timing and abundance of expression. Viral
expression in the previously described experiments was driven by the MSCV promoter
and lead to continual overexpression. Additionally, alternative splicing isoforms of the
fusions likely have functional consequences because they were observed at a high
frequency in ZNF384-rearranged patient samples. Another shortcoming of the viral
approach was that it does not permit endogenous splicing. Finally, an additional point to
consider when modelling mutations in the appropriate context, is the cell of origin.
Modelling concomitant lesions is also challenging because the order of mutation
acquisition is likely important. Genomic characterization of patient diagnosis and relapse
samples supports that chromosomal rearrangements are initiating lesions and tumor
suppressor or signaling alterations are secondary81-83. The viral models add all mutations
to the cells simultaneously or add mutations to ARF-null cells, but a more appropriate
model would add mutations in the proper sequence.
In addition to these shortcomings of modeling using a viral approach, I faced
many challenges when trying to generate high titer ZNF384 fusion virus. Wild type
ZNF384 reliably yielded high-titer virus, however, the fusions required optimization at
every step, from expression plasmid to transduction method. Interestingly, viral titer was
linked to N-terminal partner with EP300-ZNF384 consistently having the lowest titer and
TCF3-ZNF384 having the highest titer.
A more accurate model of ZNF384 rearrangements, that avoids the challenges and
limitations of lentiviral expression, would disrupt one of each wild type allele and fusion
expression would be controlled by the endogenous locus. With this in mind, I designed
two genetically engineered mouse models (GEMM) with conditional fusion expression at
the endogenous locus. I chose two models because each had its own advantages and
limitations. The first model utilized Lox sites on chromosomes 6 and 15 that created a
chromosomal rearrangement in the presence of Cre-recombinase. This model perfectly
recapitulated the genomic event in patients which lead to expression of EP300-ZFP384
and allowed splicing to happen naturally. The limitations of this approach were the
possible low recombination efficiency due to the distance between Lox sites and the lack
of an epitope tag for mechanistic experiments. The second approach inserted a reverse
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orientation Zfp384-HA-V5 cDNA minigene into intron 5 of Ep300 that could be flipped
by Cre-recombinase to create Ep300-Zfp384-HA-V5. The advantage of this model was
the high recombination efficiency and the presence of an epitope tag. However, this
approach did not disrupt one allele of Zfp384 and did not permit splicing.
In addition to conditional fusion expression at the endogenous Ep300 promoter, another
benefit of using these GEMMs was the ability to study the effect of fusion expression on
hematopoiesis. It was described in Chapter 2 that mouse HSPCs expressing fusions,
without addition lesions, did not engraft. The effect on hematopoiesis could not be
investigated, but this model forced fusion expression in vivo and the effect on lineage
output could be assessed. Additionally, if fusion expression transforms cells but does not
drive leukemia, concomitant genetic alterations can be introduced to perturb additional
critical pathways and facilitate leukemogenesis.

Methods

Cre-recombinase driven Ep300-Zfp384 mouse model
Zfp384 intron2.Lox66 mice were generated using CRISPR-Cas9 technology to insert a
Lox66 site into intron 2 of Zfp384 (Entrez gene ID 269800), the mouse homolog of
ZNF384. Pronuclear-stage C57BL/6N/J zygotes were injected by the SJCRH
Transgenic/Gene Knockout Shared Resource with a single sgRNA (Zfp384_i2_LOXPGuide 01, 50 ng/μL (Appendix B Table B-1) designed to introduce a double stranded
DNA break into intron 2 of the Zfp384 gene, a human codon-optimized Cas9 mRNA
transcript (100 ng/μL) and a 200 nucleotide single stranded DNA molecule containing the
desired mutations (Zfp384-i2-lox66-HDR, 2 pmol/μL (Appendix B Table B-1).
Approximately 25 injected zygotes were surgically transplanted into an infundibulum of
0.5 day post coitus pseudo pregnant CD-1 females and newborn mice carrying the edited
alleles were identified by PCR and Sanger sequencing using primers Zfp384-i2-LOXPF01 and Zfp384-i2-LOXP-R02. A similar strategy was used to generate Ep300 intron6.Lox71
mice by targeting intron 6 of Ep300 gene (Entrez gene ID 328572). Ep300 intron6.Lox71
sgRNA (Ep300_i6_LOXP-Guide 01), repair template (Ep300-i6-lox71-HDR) and PCR
primers (Ep300-i6-LOXP-F01 and Ep300-i6-LOXP-R02) sequences are shown in
Appendix B Table B-1. sgRNAs were designed and generated as described previously
84
. Cas9 mRNA transcripts were also generated as described previously 84. The target site
for each sgRNA is unique in the mouse genome and no potential off-target site with
fewer than three mismatches were found using the Cas-OFFinder algorithm 85. Loci were
genotyped by PCR using primers and subsequent Sanger sequencing of the PCR
amplicon (Appendix B Table B-1). Zfp384 intron2.Lox66 and Ep300 intron6.Lox71 mice were
bred together to generate homozygotes for both loci. This mouse was then crossed with a
Vav-cre mice 86 to generate heterozygous chromosomal rearrangements in hematopoietic
cells. Peripheral blood collected by retroorbital bleed and immunophenotyping using a
panel of multilineage markers was performed as described in Chapter 2 methods.
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Validation and FISH
Chromosomal rearrangement of the DNA and expression of the fusion transcript
was validated using PCR. Peripheral blood was collected from 6-9 month old mice and
DNA extracted using the AllPrep DNA/RNA Mini Kit (Qiagen) according to the
manufacturer’s recommendations. Breakpoint DNA was amplified using the primers
listed (Appendix A Table A-1) and the PCR product was electrophoresed on a 1%
agarose gel. The PCR reaction was cleaned up using ExoSAP-IT (Applied Biosystems)
and validated by Sanger sequencing. RNA was isolated from 12 month old mice spleen
using the AllPrep DNA/RNA Mini Kit (Qiagen) and used to make cDNA with the
Superscript III First-Strand Synthesis System (Invitrogen). The fusion gene was
amplified by PCR using the primers listed (Appendix A Table A-1). Similarly, the PCR
product was electrophoresed on an agarose gel, cleaned up using ExoSAP-IT (Applied
Biosystems), and validated by Sanger sequencing. A sequential hybridization FISH assay
was designed by Marc Valentine in the St. Jude Cytogenetics Core to detect disruption of
Ep300 combined with fusion of Zfp384 to the 5’ portion of Ep300. This approach uses
an initial break apart assay of the Ep300 locus in the first hybridization followed by
detection of fusion between the 5’ Ep300 portion and Zfp384. Bacterial artificial
chromosome (BAC) clones representing the 5’ and 3’ ends of Ep300 gene were used as
probes for determining if a rearrangement of the Ep300 gene was present. Clones RP24368C10 and RP23-131J20 were used for the 5’ and 3’ probes, respectively. Purified DNA
was labeled with Alexafluor 488 dUTP for the 3’ probe or Alexafluor 594 dUTP for the
5’ probe. The 3’ Zfp384 probe used BAC RP23-356F10 and labelled with Alexafluor 488
dUTP. Mouse bone marrow cells were fixed and hybridized. For the analysis 270
interphase nuclei were scored for either pairing or disruption of signal from the 5’ and 3’
Ep300 probes. Slide coordinates were recorded for cells without pairing and a second
hybridization was performed with the Zfp384 probe. Images at the same coordinates were
taken and compared to the original images. This assay was designed to detect disruption
of the Ep300 locus and subsequent fusion to the Zfp384 allele.

Ep300-Zfp384-V5-HA conditional mouse
The Ep300-Zfp384 conditional mouse model was created by Biocytogen (Beijing,
China). Homologous regions 4.1 kb upstream of Ep300 exon 6 and 5.1 kb downstream of
exon 6 were subcloned from a BAC clone from C57BL/6J mouse genomic BAC library.
A LoxP site was inserted upstream of exon 6. Downstream of exon 6 the following
sequences were inserted: an FRT-flanked Neo-resistance positive-selection cassette; a
mLoxp sequence; a reverse-orientation cDNA minigene containing Ep300 exon 6,
Zfp384-V5-HA, and polyA tail; a LoxP sequence; and a mLoxp sequence. After
linearization, the targeting vector was transfected into C57BL/6 embryonic stem cells by
electroporation. ES cells were selected by G418 treatment and screened by PCR and
Southern blotting. Seven positive clones were identified by Southern blotting with a 5’
probe, a 3’ probe, and a 5’ Neo probe. Ten positive clones were injected into Balb/c
blastocysts and implanted into pseudopregnant females. Chimeric mice were crossed with
C57BL/6 mice to obtain F1 mice carrying the recombinant allele containing the floxed
Ep300-Zfp384-V5-HA allele and the neomycin selection cassette. Mice were bred with
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Flipase expressing mice to remove the neomycin selection cassette. To generate
conditional Ep300-Zfp384-V5-HA fusion mice, mice homozygous for the floxed alleles
of Ep300-Zfp384-V5-HA were crossed with Vav-Cre mice 86.
Peripheral blood collected by retroorbital bleed and immunophenotyping was
performed as described in Chapter 2 methods. Flow analysis of the HSPCs compartments
was performed using the following antibodies: B220-Alexa700 (eBioscience, 56-045282, RA3-6B2, 1:100); Gr1-BV711 (Biolegend, 108443, RB6-8C5, 1:100); Ter119-APCCy7 (BD Bioscience, 560509, TERR-119, 1:200); CD3-APC (BD Bioscience, 553066,
145-2C11, 1:100); Mac1-BV605 (Biolegend, 101237, M1/70, 1:50); CD41-BUV396 (BD
Bioscience, 564056, MWReg30, 1:100); CD34-BV421 (BD Bioscience, 562608,
RAM34, 1:100) and CD19-PE-Cy7 (BD Bioscience, 552854, 1D3, 1:100). Animals that
became moribund were euthanized, and blood, bone marrow, and spleen were analyzed
using morphology, flow cytometry and histopathologic analysis as described in Chapter 2
methods.
For transplantation experiments, mouse pre-treatment, cell isolation, transduction,
transplantation, monitoring, and tumor characterization were performed as described in
Chapter 2 methods.

Statistical analysis
Data analyses were performed using Prism version 8.4.3 (GraphPad). Data are
presented as means ± SD. Significance was determined using 2way ANOVA Sidak’s
multiple comparison test. Kaplan-Meier analysis and the Mantel-Cox log-rank test were
used for survival data.

Single cell RNA-sequencing (sc-RNA-seq)
Mouse bone marrow cells were isolated into cold phosphate-buffered saline (PBS)
supplemented with 2% bovine serum albumin (BSA) to generate single cell suspensions.
Red blood cells (RBCs) were removed using red blood cell lysis buffer (BioLegend),
resuspended in PBS/2% BSA, and filtered through a 40μm cell strainer. An aliquot of
1X106 cells was removed as bulk bone marrow. Lineage depletion was performed on the
remaining cells using the mouse Lineage Cell Depletion Kit (Miltenyi Biotech) according
the manufacturer’s recommendations. Lineage negative cells were then stained with
streptavidin-APC (Biolegend, 405207, 1:100). Live (DAPI negative) cells were purified
by fluorescence-activated cell sorting from the bulk one marrow samples and live,
lineage negative (APC negative) cells were purified from the lineage negative samples.
Cells were washed and counted. Sc-RNA-seq libraries were generated using Chromium
10X v3.1 (10X Genomics) by combining 5000 bulk bone marrow cells and 5000 lineage
negative cells for each sample.
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Sc-RNA-seq analysis
Single cell data generated using 10X Genomics (http://www.10xgenomics.com)
3’ gene expression kit (v3.1) was aligned and quantified using Cell Ranger (v5.0.0)
against mouse genome GRCm38 (refdata-gex-mm10-2020-A). Cells with fewer than 200
or higher than 6000 features, or mitochondria content higher than 5% were removed. The
feature counts data of the selected cells from one wild type and two samples expressing
EP300-Zfp383-V5-HA transcript were merged together using canonical correlation
analysis87 from Seurat package (https://satijalab.org). A total of 21705 cells were used for
further analysis. Clusters of cells were identified using Seurat, partitioned into 5 major
superclusters using Monocle388, and characterized based on gene expression of major
haemopoietic cell types. Differential expression between wild type and EP300-Zfp383V5-HA was performed for the three major partitions separately using Seurat.

Results

Conditional chromosomal rearrangement to generate the Ep300-Zfp384 fusion gene
The first GEMM aimed to recapitulate the chromosomal rearrangement seen in
patients that results in the EP300-ZNF384 fusion gene. Specifically, the goal was to
create a chromosomal rearrangement using one allele of each gene while maintaining one
wild type allele of each gene (Figure 3-1A). This would allow me to model the loss of
one wild type copy of each gene and also express appropriate levels of the fusion gene
under the endogenous Ep300 promoter region. To do this I used genome editing to
generate a Zfp384 mouse line with a Lox66 site in intron 2 (chromosome 6) and an Ep300
mouse line with a Lox71 site in intron 6 (chromosome 15) (Figure 3-1A). These mutant
Lox sites were chosen to prevent successive recombination from occurring. I bred these
mice together and then introduced Cre recombinase with expression controlled by the
Vav promoter, which is specific to hematopoietic cells. I confirmed the chromosomal
rearrangement in the peripheral blood by PCR and sequencing, although, the PCR
product could not be detected in all mice with both Lox alleles (Figure 3-1B, C).
Additionally, FISH analysis of bone marrow cells revealed the break apart of Ep300 and
the fusion of 3’ Zfp384 to 5’ Ep300 (Figure 3-1D). Using FISH, I could determine the
frequency of rearrangement to be between 0-47% of cells, specifically the four mice
analyzed had 0%, 1%, 31% and 47% rearranged cells, which explains why the fusion was
not detected by PCR in all samples. This novel approach of generating a chromosomal
rearrangement in vivo worked impressively well in some samples, however, there was
inconsistency in frequency from mouse to mouse. Furthermore, I validated the expression
of Ep300-Zfp384 transcript by RT-PCR and Sanger sequencing of spleen cells (Figure
3-1E, F). As these mice aged, there were not consistent changes in immunophenotype,
although a shift in hematopoiesis in a subset of positive mice began to emerge. The
peripheral blood of a subset of 11-14 month old mice had modest reduction of lymphoid
cells (B220, CD19 double positive) and expansion of myeloid cells (Mac1, Gr1 double
positive) (Figure 3-1G). No mice developed hematological disease.
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Figure 3-1. Generation of a conditional in vivo chromosomal rearrangement that
results in Ep300-Zfp384 expression.
(A) A schematic representation of Ep300 and Zfp384 with a Lox site (triangle) inserted in
intron 6 of Ep300 and intron 2 of Zfp384. In the presence of Cre recombinase, the two
Lox sites recombine to create Ep300-Zfp384. (B) Validation of the genomic Ep300Zfp384 fusion from the peripheral blood of mice by PCR. (C) Samples were validated by
Sanger sequencing, a representative electropherogram of the genomic rearrangement is
shown. (D) FISH assay demonstrating the break apart of Ep300 (left panel) and the
rearrangement of 3’ Zfp384 to 5’ Ep300 (right panel). (E) Validation of expression of
Ep300- Zfp384 fusion transcript by RT-PCR of spleen samples. (F) Samples were
validated by Sanger sequencing, a representative electropherogram of the fusion
breakpoint is shown. (G) Immunophenotype of the peripheral blood, determined by flow.
Columns show means of six replicates ± SD.
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Conditional expression of Ep300-Zfp384-V5-HA
The second GEMM knocked-in a floxed, inverted Ep300-exon6-Zfp384-V5-HA
cDNA minigene into intron 5 of Ep300 (Figure 3-2A). In the presence of Cre
recombinase, the minigene flipped into the correct orientation leading to the expression
of Ep300-Zfp384 fusion gene and disruption of full-length Ep300 (Figure 3-2A). I
crossed this Ep300intron5_e6-Zfp384-V5-HA mouse with a Vav-cre mouse to induce fusion
expression in the hematopoietic system and validated by PCR of peripheral blood
(Figure 3-2B). I then analyzed the peripheral blood immunophenotype of 2-6 month old
mice and found reduced CD19 positive B-cells (Figure 3-2C). Additionally, these mice
had an increase percent of Mac1, Gr1 double positive cells but a reduced percent of Mac1
negative, Gr1 positive cells (Figure 3-2C). Next, I performed a detailed analysis of the
HSPC compartments from the bone marrow of 4 month old mice. Bone marrow cells
expressing Ep300-Zfp384 had a similar frequency of HSC, MPP, and MEP compared to
wild type mice (Figure 3-2D). However, there was an increased frequency of CMP and
GMP cells in the fusion-expressing mouse (Figure 3-2D).
As Ep300-Zfp384 fusion-expressing mice aged, they began to develop ulcerative
colitis due to Helicobacter spp. infections and had to be euthanized. Rectal prolapse led
to euthanasia of 60% of the mice, 20% died of other causes, and only 20% survived to
old age (Figure 3-2E). The wild type controls were housed with Ep300-Zfp384 fusion
mice and also had Helicobacter spp. infections but did not develop colitis, suggesting an
impaired immune response. The bone marrow of these mice had myeloid hyperplasia and
a reduction of lymphoid cells (Figure 3-2F).
To better understand the intricacies of this altered hematopoiesis, I performed scRNA-seq on fresh bone marrow from 6 week old mice. Each sample contained 5000 bulk
bone marrow cells and 5000 lineage negative cells to enrich for the stem and progenitor
populations. Twenty unique transcriptional clusters in wild type and fusion samples were
identified (Figure 3-3A). Expression of the fusion did not result in novel clusters or lost
clusters (Figure 3-3A). Using cell-type defining gene lists from published sc-RNA-seq
data, I grouped clusters into the following 3 partitions: stem and progenitor; monocyte
and neutrophil; or erythrocyte, basophil, megakaryocyte (Figure 3-3B)89,90. Comparison
within each partition revealed subtle changes in transcriptional programs. In the stem and
progenitor partition, which includes clusters 0, 6, 8, 12, and 19; cells from the Ep300Zfp384-V5-HA mouse had lower expression of dendritic cell and cord blood signature
genes and increased expression of genes regulated by hematopoietic lineage specifying
transcription factors, such as GATA1 and KLF4 (Figure 3-3C). The monocyte and
neutrophil partition, which includes clusters 2, 3, 4, 7, 9, and 16; also had decreased
expression of dendritic cell and cord blood signature genes and increased expression of
signaling genes compared to wild type cells (Figure 3-3D). In the erythrocyte, basophil,
megakaryocyte partition, which includes clusters 1, 5, 10, 14, 15, and 17; cells from the
fusion mouse had reduced expression of mature granulocyte genes (Figure 3-3E).
Overall, this suggests that fusion-expressing cells are transitioning from stem and
progenitor cells toward specific lineages but have reduced granulocyte maturation.

45

Figure 3-2. Generation of a mouse model that conditionally expresses Ep300Zfp384-V5-HA.
(A) A schematic representation of the reverse-orientation minigene that was knocked into
intron 6 of Ep300. Upon Cre-driven recombination, the minigene is flipped and replaces
endogenous exon 6. The primers used for PCR validation are shown in red arrows. (B)
Validation of the genomic Ep300-Zfp384-V5-HA fusion from the peripheral blood of
mice by PCR. (C) Immunophenotype of the peripheral blood, determined by flow.
Columns show means of four replicates ± SD. ****P<0.0001 (D) HSPC compartment
characterization by flow analysis of bone marrow cells. Lineage negative, Kit+ (LK);
lineage negative, Sca1+, Kit- (LSK); hematopoietic stem cell (HSC); multipotent
progenitor 2 and 3 (MPP2/3); multipotent progenitor 4 (MPP4); common myeloid
progenitor (CMP); megakaryocyte erythroid progenitor (MEP); granulocyte monocyte
progenitor (GMP). (E) Survival curves of Ep300-Zfp384-V5-HA mice and litter mate
controls. ****P<0.0001 (F) Immunophenotyping from a representative mouse showing
the bone marrow lacks CD19 or CD3 positive cells and an expansion of myeloid-lineage
cells.
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Figure 3-3. Single cell RNA-sequencing of Ep300-Zfp384-V5-HA mouse bone
marrow.
(A) Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction
for wild type (top panel) or EP300-ZFP384-V5-HA (bottom panel) bone marrow cells
showing 20 independent clusters. (B) UMAP showing that similar clusters were grouped
together to make 3 partitions. (C) Gene expression was compared between wild type and
EP300-ZFP384-V5-HA samples in the stem and progenitor partition, (D) monocyte and
neutrophil partition, or (E) erythrocyte, basophil, megakaryocyte partition.
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To directly examine whether expression of Ep300-Zfp384 altered hematopoiesis
and primed the cells for leukemic transformation but required a second hit for leukemia
to develop, I isolated HSPCs from 12 week old wild type or Ep300-Zfp384, Vav-cre
mice, transduced with either CL20-MSCV-ires-GFP empty vector or CL20-MSCVNRASG12D-ires-RFP, and transplanted into recipient mice (Figure 3-4A). Mice
transplanted with Ep300-Zfp384, Nras G12D expressing cells developed myeloid and
mast cell leukemias with an average latency of 63 days (Figure 3-4B). These mice had
splenomegaly and these tumors were serially transplantable (Figure 3-4C). Surprisingly,
mice transplanted with Ep300-Zfp384, empty vector expressing cells also developed
leukemia with an average latency of 118 days (Figure 3-4B). The bone marrow had no
lymphoid cells and an expansion of Mac1, Gr1 double positive cells (Figure 3-4D). In
contrast, Nras G12D only tumors were T-ALL or B-ALL with an average latency of 114
days, which duplicates data shown previously (Figure 3-4B, D).

Discussion
I have successfully created a Cre-driven chromosomal rearrangement involving
chromosomes 6 and 15 in vivo. This rearrangement led to expression of the fusion
transcript Ep300-Zfp384, which is seen in patients. The frequency of rearrangement is
inconsistent, and no mice developed phenotypes. This is likely because the Lox sites are
located on different chromosomes and recombination is rare. However, it is promising to
see that although the rate of recombination is low, some mice had greater than 30% of
cells with the rearrangement, suggesting that acquisition of the fusion results in selective
advantage. A possible strategy for encouraging malignancy development is to transplant
bone marrow from these mice into recipients. This would alleviate issues related to aging
mice and the transplantation might promote expansion of the fusion-containing cells that
may reveal a phenotype.
The second GEMM was also designed to generate Ep300-Zfp384 but using a
different approach. I utilized a floxed HA- and V5-tagged Zfp384 minigene to predictably
result in conditional expression of the fusion. Although this model does not disrupt one
normal copy of Zfp384 or have splicing potential, recombination was probable and the
epitope tags are useful for downstream analysis.
The expression of Ep300-Zfp384-V5-HA in all hematopoietic cells led to a
skewing in hematopoiesis that is apparent throughout differentiation. There was an
increased frequency of myeloid progenitor cells in the bone marrow and increased
granulocytes in the peripheral blood. Interestingly, the blood also had a reduced
frequency of lymphoid cells. These mice frequently died of rectal prolapse due to a
Helicobacter spp. infection. The sensitivity of the colon to this infection could be caused
by the expansion of myeloid cells that increase inflammation or by the lack of lymphoid
cells to fight the infection. The skewing of hematopoiesis suggests that EP300-ZFP384,
and possibly wild type ZNF384, is an important regulator of the lymphoid-myeloid fate
but further mechanistic studies need to formally investigate that.
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Figure 3-4. Leukemia development in mice transplanted with Ep300-Zfp384-V5HA HSPCs expressing NRAS G12D.
(A) The workflow for transplantation assays. Bone marrow was isolated from Ep300Zfp384-V5-HA or C57BL/6 mice, enriched for HSPC, transduced with empty vector or
NRAS G12D, and sorted before transplanting into mice. (B) Survival curves in primary
recipients transplanted with indicated cells. **P=0.0067 (C) White blood cell (WBC)
count (left panel) or spleen weight (right panel) at death in mice transplanted with
indicated cells. The mean expression is shown by the horizontal line in the scatter dot plot
and the error bars represent the SD. *P=0.0297 (D) Immunophenotype, determined by
flow analysis, reveals a unique immunophenotype for each group.

50

Sc-RNA-seq of the bone marrow of these mice revealed that expression of the
fusions did not lead to gain or loss of cell clusters compared to wild type bone marrow.
Instead, subtle changes in transcriptional programs were observed within clusters.
Specifically, Ep300-Zfp384-V5-HA mouse bone marrow cells had increased lineagespecifying gene expression with reduced stem/progenitor and mature granulocyte
expression signatures. This supports the in vivo work that showed skewing toward
myeloid differentiation but a block in myeloid maturation. Further analysis of this data
aims to perform this same gene expression comparison in each cluster with the hope of
revealing a more detailed description of how EP300-ZFP384 alters hematopoiesis.
Finally, the transplant experiment using Ep300-Zfp384-V5-HA expressing cells
with NRAS G12D or empty vector nicely modeled the acquisition of mutations. I saw the
progression from a leukemia-primed cell state to full-blown leukemia driven by gaining a
mutation or cellular stress.
This is the first GEMM of ZNF384 rearrangements and provides a powerful tool
for further studying how ZNF384 fusions alter hematopoiesis and prime cells for
transformation. Specifically interesting, are the roles of concomitant lesions or other
stresses that could be explored using this mouse. Additionally, the V5-HA epitope tag is
valuable for monitoring fusion expression using intracellular staining followed by flow
analysis or immunofluorescence. Flow analysis could be used to monitor cell-type
specific expression of the fusion and immunofluorescence could be used for cellular
localization analysis. The epitope tag is also useful for mechanistic studies to investigate
chromatin binding and protein interactions. It would be particularly interesting to explore
how EP300-ZFP384 binding differs between hematopoietic subpopulations. Finally, the
Ep300-Zfp384-V5-HA transplantation model could be a tractable model for in vivo
therapeutic studies.
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CHAPTER 4. INVESTIGATING THE ROLE OF ZNF384 FUSIONS IN
HEMATOPOEISIS AND LEUKEMOGENESIS USING HUMAN CD34 CELLS

Introduction
Human cord blood is a rich source of hematopoietic stem and progenitor cells,
which are characterized by expression of the cell surface marker, CD34. These cells can
be utilized to study hematopoiesis and leukemogenesis using well-established in vitro and
in vivo assays. Using an improved sorting scheme described by Notta et al, CD34 cells
can be further fractionated by fluorescence-activated cell sorting into stem and progenitor
subpopulations so that the effect of fusion expression can be monitored in multiple
potential cells of origin91. Specifically, there are at least five subpopulations defined by
immunophenotypic criteria; the hematopoietic stem cell (HSC), the multipotent
progenitor cell (MPP), the common myeloid progenitor (CMP), the megakaryocyteerythroid progenitor (MEP), and the granulocyte-monocyte progenitor (GMP).
A standard in vitro approach to investigate cellular transformation is the colony
forming unit (CFU) assay. In contrast to the mouse CFU assays of leukemia fusion
oncoproteins, analogous assays performed in human cells less commonly result in serial
replating, a surrogate measure of transforming potential. Thus, the main observations of
the human assays are changes in colony morphology or immunophenotype. Although still
a useful assay, it has been shown that there are technical issues with the CFU that lead to
biased results91. In myeloid CFU assays CMPs give rise to myeloid (My), erythroid (Er),
or megakaryocyte (Mk) colonies, GMPs generate My colonies only, and MEPs generate
Er and/or Mks. The results from this standard CFU assay guided development of the
classical human hematopoietic hierarchy. However, if CMPs, GMPs, or MEPs are plated
using an elegant single cell differentiation assay they generate colonies of all myeloid
lineages91. These results suggest that CFU assays create an output bias when a pool of
cells is plated together.
Human cells can be transplanted into immunodeficient mouse models for
hematopoiesis or leukemogenesis studies. The most commonly used strain is NOD-scid
Il2Rγnull (NSG) which is a background strain of non-obese diabetic mouse (NOD) with
two mutant genes, Prkdcscid and interleukin-2 receptor (Il-2R) γ-chain 92. The NSG strain
has impaired B- and T-cell function, and lacks natural killer cells 92. This strain has been
further genetically modified to create the NSG-SGM3 which expresses the human
cytokines stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), and interleukin-3 (IL-3) 93. These mice have improved myeloid cell
engraftment compared to the NSG strain.
As my experiments utilizing lentiviral expression of human ZNF384 fusions in
mouse cells resulted in variable transduction efficiency and cellular transformation, I
hypothesized that modeling in CD34 cells would more accurately capture the cellular
context of ZNF384 fusions. I used traditional CFU and the single cell differentiation
assay as complementary approaches to detect lineage skewing caused by expression of
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ZNF384 fusions. Additionally, transplant experiments were performed using both NSG
and NSG-SGM3 strains to compare engraftment and leukemogenesis. Combining these
experimental approaches enabled investigation of the effect of ZNF384 fusion expression
on human hematopoiesis and leukemia development.

Methods

Isolation of CD34 cells from human cord blood
De-identified human cord blood samples were obtained from Duke University Carolinas Cord Blood Bank (Durham, NC) with informed consent. Cord blood from
multiple donors was pooled and processed 24-48 hours post-delivery. Mononuclear cells
were enriched using Accu-Prep (Accurate Chemical) and SepMate-50 tubes
(STEMCELL Technologies). CD34 positive selection was performed using CD34
Microbead kit UltraPure (Miltenyi Biotec).

Human methylcellulose assay
CD34 cells were cultured in X-VIVO 10 (Lonza), supplemented with 1% bovine
serum albumin (Sigma), recombinant human SCF (100 ng/mL), FLT-3 ligand (100
ng/mL), thrombopoietin (TPO)(50 ng/mL), and IL-7 (10 ng/mL) (PeproTech) for 24
hours prior to transduction. Cells and viral supernatants (pCL20c MSCV-ires-GFP
lentivirus expressing the wild type or fusion genes of interest) were added to 96 well nontissue culture treated plates and maintained at 37°C for 48 hours. CD34, GFP double
positive cells were fluorescence-activated cell sorted directly into complete
methylcellulose (H4034, STEMCELL Technologies) that included β- Mercaptoethanol,
recombinant human SCF, IL-3, erythropoietin (EPO), granulocyte colony-stimulating
factor (G-CSF), and GM-CSF with the addition of recombinant human FLT-3 ligand
(20 ng/mL) and IL-6 (50ng/mL) (PeproTech). One hundred cells were plated in duplicate
and colonies were allowed to differentiate for 10 days before counting and morphologic
assessment of hematopoietic colonies. Flow cytometry analysis using a panel of
multilineage markers (CD34 APC-Cy7 (BioLegend, 343513, Clone 581, 1:50), CD38
PE-Cy7 (BD bioscience, 335790, clone HB7, 1:50), CD45 Alexa700 (Invitrogen,
MHCD4529, HI30, 1:50), CD19 BV605 (BD bioscience, 562653, SJ25C1, 1:50), CD33
BV711 (BioLegend, 366624, clone P67.6, 1:50), CD10 BV421 (BD bioscience, 562902,
clone HI10a, 1:50)) was performed on the GFP positive cells to determine colony
immunophenotype.

MS-5 single cell differentiation assay
Cells were fluorescence-activated cell sorted for HSC, MPP, CMP, MEP, or GMP
populations using the following antibodies: CD45RA FITC (BD Biosciences, 561882,
clone HI100, 1:50), CD90 PE (BD Biosciences, 561970, clone 5E10, 1:50), CD34 APC-
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Cy7 (BioLegend, 343513, Clone 581, 1:50), CD38 PE-Cy7 (BD Biosciences, 335790,
clone HB7, 1:50), CD49f BV605 (BD Biosciences, 740416, clone GoH3, 1:50), CD71
BV711 (BD Biosciences, 563767, clone M-A712, 1:50), CD7 V450 (BD Biosciences,
642916, clone M-T701, 1:50), CD10 V421 (BD Biosciences, 562902, clone HI10a, 1:50),
CD135 A647 (BD Biosciences, 563494, clone 4G8, 1:50). HSC, MPP, CMP, MEP and
GMP populations were pre-stimulated in X-VIVO 10, 1% BSA supplemented with
recombinant human SCF (100 ng/mL), FLT-3 ligand (100 ng/mL), TPO (50 ng/mL), and
IL-7 (10 ng/mL) (PeproTech) for 4 hours before adding lentivirus. Viral supernatants
(pCL20c MSCV-ires-GFP lentivirus expressing the WT or ZNF384 fusion genes of
interest) were added and GFP positive cells were isolated by fluorescence-activated cell
sorting 72 hours after transduction.
Ninety-six well flat bottom plates (Nunc, Thermo Fisher) were coated with 0.2%
gelatin prior to seeding 1.5 x 103 MS-5 cells (Creative Bioarray) in MyeloCult media
(H5100, STEMCELL Technologies) supplemented with hydrocortisone (1µM/mL). Cells
were allowed to adhere for 48 hours prior to cell sorting. Before cell sorting, media was
changed to StemPro-34 SFM with nutrients (Life Technologies) supplemented with
penicillin, streptomycin, L-glutamine, lipids (STEMCELL Technologies), and the
following recombinant human cytokines: SCF (100ng/mL), FLT-3 ligand (20ng/mL),
TPO (100ng/mL), EPO (3ng/mL), IL-6 (50ng/mL), IL-3 (10ng/mL), IL-11 (50ng/mL),
GM-CSF (20ng/mL), IL-2 (10ng/mL) and IL-7 (20ng/mL) (PeproTech). GFP positive
cells were fluorescence-activated cell sorted into each well. One week after sorting, fresh
media was added to the wells. Two weeks after sorting, the contents of each well was
harvested and analyzed by flow cytometry. The following antibodies were used to assess
lineage: CD41 APC (BioLegend, 303709, clone HIP8, 1:50), CD235a PE (BioLegend,
349106, clone HI264, 1:50), CD45 APC-H7 (BD Biosciences, 560178, clone 2D1, 1:50),
CD11b PE-Cy7 (BioLegend, 301322, clone ICRF44, 1:50), CD15 BV605 (BD
bioscience, 562980, clone W6D3, 1:50), and CD33 BV711 (BioLegend, 366624, clone
P67.6, 1:50). Immunophenotype was determined when there were at least 10 GFP
positive cells.

Establishment of xenografts
CD34 positive cells were pre-stimulated in X-VIVO 10 supplemented with 1%
BSA, and recombinant human SCF (100ng/mL), FLT-3 ligand (100ng/mL), TPO
(50ng/mL), and IL-7 (10ng/mL) (PeproTech) for 24 hours before adding lentivirus. Cells
and viral supernatants (pCL20c MSCV-ires-GFP lentivirus expressing the wild type or
fusion genes of interest) were added to non-tissue culture treated plates and maintained at
37°C. Twenty-four hours after transduction, cells were collected and 3.0 x 104 cells were
transplanted through intrafemoral injections into sub-lethally (250 Rad) irradiated 8-12
week old NSG or NSG-SGM3 mice (Jackson Laboratory). A portion of cells were
retained in liquid culture and the percent of GFP positive cells was determined by flow
cytometry 72 hours post-transduction. Animals that became moribund were euthanized,
and blood, bone marrow, and spleen were analyzed for evidence of leukemia, using
morphology, flow cytometry, and histopathologic analysis. Post-mortem flow analysis
using a panel of multilineage markers (CD34 APC-Cy7 (BioLegend, 343513, Clone 581,
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1:50), CD38 PE-Cy7 (BD Biosciences, 335790, clone HB7, 1:50), CD45 Alexa700
(Invitrogen, MHCD4529, HI30, 1:50), CD19 BV605 (BD Biosciences, 562653, SJ25C1,
1:50), CD33 BV711 (BioLegend, 366624, clone P67.6, 1:50), CD10 BV421 (BD
Biosciences, 562902, clone HI10a, 1:50)) was performed on the GFP positive population
to determine the lineage of disease in engrafted samples. For secondary transplantation,
sub lethally irradiated (250 Rad) 8-12 week old NSG-SGM3 mice were injected
intrafemorally with 6.0 x 105 unsorted cells or 5.0 x 104 fluorescence-activated cell
sorted; CD34, GFP double positive, bone marrow cells from the primary leukemic mice.
Statistical analyses were performed as described in Chapter 2 methods.

Leukemia subtype analysis of xenograft tumors
RNA was extracted from 1 x 106 sorted tumor cells using AllPrep DNA/RNA
Mini Kit (Qiagen). Transcriptome sequencing (RNA-sequencing) was performed using
the TruSeq library preparation on the Illumina HiSeq 2000 platform as previously
described75. Sequencing was paired end and performed using low input, unstranded for
the xenograft tumors (n=6). Paired-end reads from RNA-seq were aligned to hg38
reference genome and final BAM files were constructed. To compare with tumors of BALL subtypes defined by Gu et al which were sequenced using either stranded or nonstranded library protocols, enrichment analysis of 14 B-ALL subtypes was performed
using single sample GSEA 4,94. Relative enrichment score (Z-score) was displayed in the
heatmap.

Results

ZNF384 fusions alter human hematopoiesis in vitro
The effect of ZNF384 fusions on human hematopoiesis was assessed by
lentivirally expressing wild type ZNF384, TAF15-ZNF384, TCF3-ZNF384, EP300ZNF384, or lentiviral vector expressing GFP only in human CD34 positive cells isolated
from cord blood. When cells were plated in methylcellulose differentiation assays, there
were no differences in the number of colonies that formed or the colony type, as
determined by morphology (Figure 4-1A). Additionally, none of the conditions resulted
in the ability to serially replate. However, when cells were assessed by flow cytometry to
determine the immunophenotype, there were striking differences in the cells expressing
ZNF384 fusions compared to controls (Figure 4-1B). Cells expressing TAF15-ZNF384
or EP300-ZNF384 were nearly all CD45 and CD33 positive (Figure 4-1B, C). Cells also
expressed lymphoid markers CD10 or CD19, resulting in CD19, CD33 double positive
cells (Figure 4-1B, C). Cells expressing TCF3-ZNF384 had slightly elevated expression
of similar markers when compared to empty vector or wild type ZNF384 expressing cells
(Figure 4-1B, C).
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Figure 4-1. Colony forming assays in human CD34 cells.
(A) CFU of CD34 human cord blood cells expressing empty vector, wild type, or fusions.
Columns show means of two replicates ± SD. Colonies were scored based on
morphology; macrophage (CFU-M), granulocyte, erythrocyte, macrophage,
megakaryocyte (CFU-GEMM), granulocyte, macrophage (CFU-GM), burst forming uniterythroid (BFU-E), or erythroid (CFU-E). (B) Cells harvested from CFU were subjected
to flow cytometry. Fusion expressing cells have an expansion of CD45 and CD33
positive cells compared to controls. Fusion samples also have CD19, CD33 double
positive cells (C) Representative immunophenotype is shown.
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To further analyze the effects of TCF3-ZNF384 expression on hematopoietic
differentiation in vitro, I utilized the single-cell differentiation assay developed by Notta
et al (Figure 4-2A)91. I fluorescence-activated cell sorted human CD34 positive cells into
the following stem and progenitor population: HSC, MPP, CMP, MEP, GMP (Figure 42B). I then lentivirally expressed empty vector, wild type ZNF384, or TCF3-ZNF384 and
fluorescence-activated cell sorted single GFP positive cells into 96 well plates to perform
a myeloid-erythroid differentiation assay. After two weeks in culture, the
immunophenotype of the colonies that formed was assessed to determine the lineage
potential of each cell (Figure 4-2A). Based on expression of myeloid and erythroid
markers, colonies could be scored as erythroid, myeloid, megakaryoblast,
erythroid/megakaryoblast, or a mixture of erythromyeloid cells (Figure 4-2C). HSCs that
expressed TCF3-ZNF384 had an increased colony forming efficiency compared to empty
vector and wild type (Figure 4-3A). MPP and CMP cells had similar number of colonies
between each group while MEP and GMP cells expressing the fusion had a reduced
colony forming efficiency (Figure 4-3A). Additionally, the majority of colonies that
arose from HSC, MPP, or CMP cells expressing TCF3-ZNF384 were not able to be
classified into the designated myeloid/erythroid categories and therefore were denoted as
“Other” (Figure 4-3A). These cells did not express GlyA, CD41, CD11b, or CD15 but
were positive for CD45 and CD33 (Figure 4-3B). This suggests that early stem and
progenitor cells are more sensitive than later progenitors to cellular transformation by
TCF3-ZNF384 expression and that cells are beginning myeloid differentiation but remain
immature.

Xenograft models of TCF3-ZNF384 leukemia
Next, I lentivirally expressed empty vector, wild type ZNF384, TAF15-ZNF384,
TCF3-ZNF384, or EP300-ZNF384 in CD34 cells and transplanted into sub-lethally
irradiated NSG or NSG-SGM3 mice. NSG-SGM3 mice transplanted with cells
expressing TCF3-ZNF384 developed leukemia with a mean latency of 83 days (Figure
4-4A). Flow cytometry analysis of the bone marrow revealed sustained expression of
CD34 in 35% cells compared to 2% in control mice. Moreover, tumors expressed CD33,
CD19, and MPO; which fulfils the requirements for a diagnosis of B/myeloid mixed
phenotype acute leukemia (Figure 4-4B, C)1. Tumors were fluorescence-activated cell
sorted for GFP positive cells and transplanted into recipient NSG-SGM3 mice, but no
secondary tumors arose. Another attempt at secondary engraftment was made by
fluorescence-activated cell sorting CD34, GFP double positive cells from the tumors to
enrich for the leukemia stem cells. These cells were transplanted into sublethally
irradiated NSG-SGM3 recipient mice, but again no secondary tumors arose. NSG mice
transplanted with TCF3-ZNF384 expressing cells had engraftment but did not develop
hematopoietic malignancies.
The same transplantation experiment was performed with CD34 cells expressing
TAF15-ZNF384 or EP300-ZNF384. Neither fusion gene led expansion of GFP positive
cells in the peripheral blood or bone marrow in NSG or NSG-SGM3 mice. Mice were
euthanized due to age and there were no signs of leukemia development.
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Figure 4-2. Single cell differentiation assay in setup.
(A) The workflow for single-cell differentiation assays. CD34 cells isolated from cord
blood were sorted into stem and progenitor compartments, transduced with empty vector,
wild type, or TCF3-ZNF384, single cells were sorted into myeloid differentiation media,
and colony were assessed by immunophenotype 15 days later. (B) The fluorescenceactivated cell sorting schema used to collect hematopoietic stem cell (HSC), multipotent
progenitor (MPP), common myeloid progenitor (CMP), megakaryocyte-erythroid
progenitor (MEP), or granulocyte-monocyte progenitor (GMP) populations. (C) An
example of the immunophenotype criteria for designating colonies erythroid only (Er),
myeloid only (My), megakaryocyte only (Mk), or a combination of cell types (Mix).
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Figure 4-3. Single cell differentiation assay with CD34 cells expressing TCF3ZNF384.
(A) Cloning efficiency and lineage outcomes of single cells from indicated genotypes in
hematopoietic stem cell (HSC), multipotent progenitor (MPP), common myeloid
progenitor (CMP), megakaryocyte-erythroid progenitor (MEP), or granulocyte-monocyte
progenitor (GMP) populations. Lineage outcomes are defined as erythroid only (Er),
myeloid only (My), megakaryocyte only (Mk), a combination of cell types (Mix), or
Other. (B) Representative immunophenotype of the colonies designated Other, which
express only CD45 and CD33.
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Figure 4-4. Leukemia development in NSG-SGM3 transplanted with human
CD34 cells expressing TCF3-ZNF384.
(A) Survival curves in primary recipients transplanted with indicated cells. (B)
Immunophenotyping from a representative mouse showing tumors express CD34, CD38,
CD33, and CD19. (C) Haematoxylin and eosin staining (left panel), CD33 staining
(middle panel), and MPO staining (right panel) of sternal section. (D) Single sample
GSEA displaying relative enrichment score (Z-score) for B-ALL subtype-specific gene
lists. Experimental tumors are enriched for ZNF384-rearranged gene set
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RNA was isolated from fluorescence-activated cell sorted GFP positive spleen
cells of five leukemic mice and one empty vector control. RNA-sequencing was
performed, and samples were analyzed using single sample gene set enrichment analysis
(GSEA) to determine the enrichment for gene expression signatures of 14 defined
leukemia subtypes (Figure 4-4D). Heterogeneity of samples is required for single sample
GSEA therefore, 12 non ZNF384-rearranged patient tumor samples were included in the
analysis. Tumors generated experimentally by expression of TCF3-ZNF384 in CD34
cells had enrichment of expression of the top 250 upregulated genes in patients with
ZNF384 rearrangements (Figure 4-4D). In contrast, the empty vector-expressing cells
showed no enrichment for that gene set.

Discussion
These experiments have shown that expression of ZNF384 fusions altered
hematopoiesis in vitro and lead to undifferentiated, CD45, CD33 double positive cells
which also express CD19. The most striking cellular transformation caused by TCF3ZNF384 expression occurred in HSC, which had increased colonies in the single cell
differentiation assay. MPP and CMP had an altered immunophenotype, but colony
number was similar to controls and MEP had a colony forming disadvantage. This
suggests that fusions must occur in a stem cell or early progenitor to transform cells. The
single-cell differentiation assay is technically challenging, therefore I used TCF3ZNF384 because it produces the viral supernatant with highest transduction efficiency
compared to other ZNF384 fusions. However, expression of TAF15-ZNF384 and EP300ZNF384 yielded more striking cellular transformation compared to TCF3-ZNF384 in
mouse HSPC CFU assays, therefore, it would be interesting to see the effect of these
fusions in the single cell differentiation assay.
Additionally, transplantation experiments revealed that expression of TCF3ZNF384 in CD34 cells leads to B/myeloid MPAL in NSG-SGM3 mice. This was the first
time ZNF384 fusions were modeled in a human hematopoietic system and it was striking
to observe the immunophenotypic similarity of the arising leukemias to ZNF384rearranged patients. This observation was even more remarkable considering the poor
engraftment of primary ZNF384-rearranged patient leukemia samples in NSG and NSGSGM3 mice.
Tumors did not develop in transplanted NSG mice, in secondary transplants, or
from expression of TAF15-ZNF384 or EP300-ZNF384 which highlights the likely
importance of the interplay between cytokine stimulation, cell of origin, and fusion
partners. Fusion partner differences could also be due to technical issues such as
transduction efficiency and level of fusion oncoprotein expression. It is interesting that
for these three fusions the strength of in vitro phenotype is negatively correlated with in
vivo phenotype.
How the fusion causes this specific CD33, CD19 double positive phenotype
across in vitro assays, in vivo assays, and in patients is still unclear. I hypothesize that the
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ZNF384 fusions likely act as master regulators of differentiation-specific transcriptional
programs, which primes cells for a myeloid-lymphoid trajectory while also holding cells
in an immature state. To explore how ZNF384 fusions drive this specific phenotype I
performed a series of mechanistic studies that are detailed in the subsequent chapter.
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CHAPTER 5.

EXPLORING THE MECHANISM OF ZNF384 FUSIONS IN
CELLULAR TRANSFORMATION

Introduction
Chromosomal rearrangements involving ZNF384 are a subtype-defining lesion in
leukemia. There is a growing list of N-terminal partners that are truncated and fused to
full-length ZNF384. The diverse partners include transcription factors (EWSR1, TAF15,
TCF3), chromatin modifiers (ARID1B, CREBBP, EP300, SMARCA2, SMARCA4),
mitochondrial ATP synthase subunit (ATP5C1), kinase (BMP2K), clathrin-related
proteins (CLTC, SYNRG), and cohesion complex protein (NIPBL). The partners often
lose their functional domains and only contribute protein-interaction domains or
disordered regions to the novel fusion protein.
The observation that the fusions nearly always involve the full-length coding
sequence of ZNF384 is distinct from most other fusion oncoproteins in leukemia, in
which the protein sequences of both partners are typically truncated, and raises the
possibility that ZNF384 fusions may exert functional effects by deregulated expression of
both the wild type protein as well as a chimeric fusion oncoprotein. Additionally,
ZNF384-rearranged leukemia has a distinct gene expression profile regardless of the
fusion partner involved which suggests that these fusions have a common mechanism that
is likely through altered transcription regulation. The normal function of the N terminal
partners and their involvement in hematopoiesis, leukemia, or cancer was detailed in
Chapter 1, however, it is important to highlight a few key functions of the most common
partners to provide insight to a possible mechanism. EP300 and CREBBP are
homologous HATs that acetylate H3K27 (H3K27Ac) at enhancers and promoters to
facilitate recruitment of co-factors, opening of chromatin, and transcription activation54.
TCF3 is a transcription factor critical for normal lymphoid development and is
recurrently involved in oncogenic fusions in leukemia59. Finally, TAF15 and EWSR1 are
transcription factor subunits of the transcriptional pre-initiation complex and directly bind
and process mRNA57. Interestingly, these proteins contain an intrinsically disordered
domain that has been shown to be critical for cellular transformation when involved in
fusion oncoproteins95. Specifically, EWSR1-FLI, a driving lesion in Ewing’s sarcoma,
leads to cellular transformation by phase separation and recruitment of the SWI/SNF
subunit, BAF, to tumor-specific enhancers96.
To explore the mechanism of cellular transformation caused by ZNF384 fusions I
utilized biochemical approaches to perform an integrated analysis of chromatin
modifications and transcriptional deregulation. I investigated altered DNA binding of
fusion proteins compared to wild type using ChIP-seq. With knowledge of differential
binding, correlations with gene expression and changes in cis histone modifications could
be assessed. Finally, I addressed the possibility of altered protein interactions using IPMS.
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To perform these analyses, I first needed to identify the most relevant and useful
cell system. Suitability for modeling was defined by the cell-type similarity to patient
leukemia or presumed cell of origin; with primary tumor samples, from patients or mouse
models, being the most relevant and cell lines, such as HEK293T cells, being the least
relevant. HEK293T cells are derived from human embryonic kidney tissue and therefore
do not represent the hematopoietic environment that ZNF384 fusions occur. Although,
due to the technical challenges of working with primary cells and the technical ease of
cell lines, HEK293T cells are widely used for mechanistic studies. In the middle of this
spectrum were hematopoietic primary cells or cell lines that could be transduced to
lentivirally express ZNF384 fusion genes. Specifically, hematopoietic primary cells that
could be grown in culture for a few weeks were mouse HSPCs or human CD34 cells.
Mouse hematopoietic cell lines included an immortalized hematopoietic progenitor cell
line, EML, named for the ability to differentiate into erythroid, myeloid, or lymphoid
cells97. Additionally, Ba/F3 cells are an IL-3-dependant pro-B cell line that has been
commonly used for studying aberrant signaling and therapeutics in leukemia 98-100.
Finally, the IL-7-dependent pre-B cell line derived from ARF-null mouse bone marrow,
referred to as ARF-null pre-B cells, has been used for functional studies and modeling BALL74,80.
Usefulness was defined by abundance and availability of cells to perform these
assays and by ability to express sufficient amounts of HA-tagged fusion proteins. The HA
epitope tag is critical to distinguish between wild type and fusion proteins. This criterion
excludes patient samples, that while express fusion proteins, they cannot be readily HAtagged and expanded. To assess the usefulness of the other cell systems, I assessed
protein expression of HA-tagged wild type or ZNF384 fusions by western blot in
lentivirally transduced mouse tumor cells, primary HSPCs, and cell lines (EML, Ba/F3,
and ARF-null pre-B). Wild type and full length fusion proteins were identified in
HEK293T cells and ARF-null pre-B cells, however, were not detected in any other cells
examined. Based on this, the mechanistic studies were performed using ARF-null pre-B
cells.
The overall goal was to determine how expression of ZNF384 fusions leads to
distinct changes in gene expression and cellular transformation. The hope in
understanding how these fusions work is to reveal possible therapeutic vulnerabilities.

Methods
Pre-B cell culture establishment and maintenance was performed as described in
Chapter 2. Immunoblotting was performed as described in Chapter 2.

RNA sequencing and analysis of cell lines
Total RNA was isolated from 5 X 106 fluorescence-activated cell sorted GFP
positive ARF-null pre-B cells (indicating expression of CL20-MSCV-ires-GFP
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containing wild type or fusion inserts) using the RNeasy Mini Kit (Qiagen). The integrity
of RNA was analyzed by Bioanalyzer (Agilent) and quantitated using RiboGreen
(ThermoFisher). Libraries were prepared from total RNA with the TruSeq Stranded Total
RNA Library Prep Kit (Illumina.) Libraries were quantified using the Quant-iT
PicoGreen dsDNA assay (Life Technologies), Kapa Library Quantification kit (Kapa
Biosystems,) or low pass sequencing on a MiSeq Nano v2 (Illumina). One hundred cycle
paired end sequencing was performed on an Illumina HiSeq 2500, HiSeq 4000, or
NovaSeq 6000. RNA isolation, library preparation, and sequencing were performed on
three biological replicates.
RNA-Seq was mapped as described previously101 and HTSeq102 (version 0.6.1p1)
was used to get gene-level count and estimated FPKM based on GENCODE103 (vM9).
Voom104 was used for gene differential expression analysis after trimmed mean
normalization (TMM).

Chromatin immunoprecipitation and sequencing (ChIP-seq)
ChIP assays were carried out as described previously105. Briefly, 20 X 106 cells
were incubated for 10 minutes in 1% formaldehyde in phosphate buffered saline at room
temperature, quenched by the addition of 1/10 volume of 2.5 M glycine. Cells were then
washed three times with cold PBS containing proteinase inhibitors and lysed on ice for 10
min in lysis buffer (50 mM HEPES, pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% NP-40, 0.25% Triton X-100). Chromatin was washed twice in washing buffer (10
mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) and then twice in
shearing buffer (0.1% SDS, 10 mM Tris-HCl, pH 8, 1 mM EDTA) before resuspension in
1 ml of shearing buffer. Chromatin was sonicated in AFA fiber milliTUBEs (Covaris)
using a Covaris E210 instrument for 15 min at 5% duty cycle, intensity 4, 200 cycles per
burst at 4°C. Sheared chromatin was centrifuged for 10 min at 13,200g at 4 °C, and the
supernatant was mixed with an equal amount of ChIP dilution buffer (0.1% SDS, 30 mM
Tris-HCl, pH 8, 1 mM EDTA, 300 mM NaCl, 2% Triton X-100) before ChIP
experiments. Immunoprecipitation was initially performed with an antibody to ZNF384
(Abcam, Ab176689), HA (Abcam, Ab9110), and a normal rabbit IgG control (Santa
Cruz, Sc2027) using 2 μg of antibody per ChIP. Primers were designed for positive and
negative control regions using the publicly available ZNF384 ChIP data (ENCODE) and
regions were validated by quantitative PCR (qPCR).
To prepare ChIP–seq libraries, 10 ng of ChIP DNA was end repaired and adaptor
ligation was performed using the NEB Next ChIP–Seq Library Prep Reagent Set for
Illumina (New England BioLabs). Libraries were purified after 14 rounds of PCR
amplification with Q5 DNA Hot-Start polymerase (New England BioLabs). Each ChIP–
seq library underwent 50-cycle single-end sequencing using TruSeq SBS kit v3 on an
Illumina HiSeq 2000. After confirming synonymy between anti-ZNF384 and anti-HA,
anti-HA was used for the remaining experiments. Experiments were performed with three
biological replicates.
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ChIPmentation sequencing
ARF-null pre-B cells were fluorescence-activated cell sorted for live, GFP
positive cells (indicating expression of CL20-MSCV-ires-GFP containing wild type or
fusion inserts) and used immediately for crosslinking. One to two million cells were fixed
in 150 µl PBS with 1% PFA (Pierce) for 10 minutes before quenching with 0.125M
glycine for 5 minutes. Cells were washed twice with 150 µl cold PBS supplement with
protease inhibitors (Pepstatin, leupeptin, PMSF, and Sodium Butyrate) and pellets were
snap frozen before storing at -80C. Subsequent work was performed on ice and used cool
buffers and solutions unless otherwise specified. The pellet was lysed in 130 µl
sonication buffer (10 mM Tris-HCl pH 8.0, 2 mM EDTA pH 8.0, 0.25% SDS, and
protease inhibitors) and sonicated with a Covaris E210 sonicator (2% duty cycle, 200
cycles per burst, 105 Watts, water level 6) for 9 minutes in an AFA fiber microTUBE
(Covaris) until the size of most fragments was in the range of 200–700 base pairs. Lysates
were centrifuged at 14,000g for 10 minutes at 4°C, and the supernatant containing the
sonicated chromatin was transferred to a new tube.
The lysate was then diluted in RIPA buffer (final concentration: 10 mM Tris-HCl
pH 8.0, 1 mM EDTA pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% sodium
deoxycholate, and protease inhibitors) to a volume of 200 µl per immunoprecipitation.
The histone 3 lysine 27 acetyl (H3K27Ac) antibody (1 µl/IP, Cell Signaling catalog
#8173S) was added to the chromatin and rotated overnight at 4°C. For each
immunoprecipitation, 10 µl Protein G Dynabeads (ThermoFisher) were prepared by
washing twice and resuspending in PBS supplemented with 0.1% BSA. The beads rotated
overnight at 4°C to block to surface with BSA. The next morning, the beads were added
to antibody/chromatin mixture and rotated 2 hours at 4°C. For control libraries, an
immunoprecipitation with 2.5 µl of a nonspecific IgG rabbit antibody (SantaCruz
Sc2027) was used. Beads were washed subsequently with RIPA-LS (10 mM Tris-HCl pH
8.0, 1 mM EDTA pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% SDS and 0.1% sodium
deoxycholate)(twice), RIPA-HS (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 500 mM
NaCl, 1% Triton X-100, 0.1% SDS and 0.1% DOC) (twice), RIPA-LiCl (10 mM TrisHCl pH 8.0, 1 mM EDTA pH 8.0, 250 mM LiCl, 0.5% sodium deoxycholate and 0.5%
NP40) (twice), and 10mM Tris-HCL pH 8.0 (once). Following the wash with Tris, the
beads and Tris were transferred to a new tube and the supernatant was discarded.
Beads were then resuspended in 25 µl of the tagmentation reaction mix containing
5 µl 5X Tagmentation buffer, 19 µl nuclease free water, and 1 µl Tagment DNA Enzyme
from the Nextera DNA Sample Prep Kit (Illumina) and incubated at 37 °C for 5 minutes
in a thermocycler. The reaction was stopped by adding 150 µl of RIPA-LS and
incubating on ice for 5 minutes. The beads were washed with RIPA-LS (twice) and twice
with cold Tris-HCl pH 8.0, 1mM EDTA. Beads were then resuspended in 48 µl ChIP
elution buffer (10 mM Tris-HCl pH 8.0, 5 mM EDTA, 300 mM NaCl, and 0.4% SDS)
containing 2 µl of Proteinase K (NEB) and incubated at 55°C for 1 hour followed by
65°C for 8 hours. The beads were magnetized and supernatant was transferred to a new
tube. DNA was purified with Qiagen MinElute Kit and eluted in 22 µl Qiagen buffer EB.
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To estimate the optimum number of enrichment cycles, 2 µl of DNA was added to
a 10 µl qPCR reaction containing 0.15 µM primers, 5 µl Kapa HiFi HotStart ReadyMix
(Kapa Biosystems), 0.2 µl KAPA SYBR Rox Low 50X (Kapa Biosystems), and 0.1 µl
SYBR 100X (ThermoFisher); using the following program: 72°C for 5 minutes, 98°C for
30 seconds, 25 cycles of 98°C for 10 seconds, 63°C for 30 seconds and 72°C for 30
seconds, and a final elongation at 72°C for 1 minute. Kapa HiFi HotStart ReadyMix was
incubated at 98°C for 30 seconds before preparation of all PCR reactions (qPCR and final
enrichment PCR), to activate the hot-start enzyme. Library was amplified in a 50 µl
reaction using 20 µl of DNA, 0.75 µM primers, and 25 µl Kapa HiFi HotStart ReadyMix.
The number of cycles was determined by using the quantitation cycle (Cq) value
determined by the qPCR reaction and adding 1 (N=Cq+1). Libraries were purified using
AMPureXP beads at a beads-to-sample ratio of 1.8:1, followed by a size selection with
AMPureXP beads to recover libraries with a fragment length of 200–400 base pairs.
Input libraries were made by reserving 20 µl of input chromatin for reverse
crosslinking and Qiagen MinElute as described above. The input DNA was tagmented at
55°C for 5 minutes in 5 µl reactions containing 2.5 µl DNA, 1 µl 1:10 Tagment DNA
enzyme, and Tagmentation buffer. The DNA was cleaned up using the Qiagen MinElute
Kit and the PCR was performed as described above with 12 cycles. A detailed protocol
can be found here: https://www.medical-epigenomics.org/papers/schmidl2015/ (version
1.14).
Library preparation was performed using custom Nextera primers as described 106.
The libraries were sequenced by the Hartwell Center using the Illumina HiSeq3000/4000
platform and the 25 base pair, paired-end configuration.

ChIP-seq analysis
ChIP-seq data from anti-ZNF384, anti-HA and anti-H3K27ac were analyzed
using ENCODE pipeline (https://github.com/ENCODE-DCC/chip-seq-pipeline2).
Briefly, raw sequencing reads were mapped to mouse genome mm10 with BWA107
(version 0.7.13-r1126). Duplicated reads were marked with Picard and only uniquely
mapped reads extracted by Samtools108 were retained for analysis. Each read was
extended to estimated fragment size by SPP109 (version 1.1) and bigwig files were
generated with the track normalized to 15 million unique mapped reads. Each sample was
reviewed to confirm clear peaks by IGV110 (3.0.beta) and consistency between anti-HA
samples and anti-ZNF384 samples. Anti-HA produced stronger peaks than anti-ZNF384
and non-specific binding was not observed, therefore anti-HA was used for all ChIP-seq
experiments.
For differential binding analysis, peaks were called with MACS2111 (version
2.1.1). Differential binding analysis was performed using DiffBind R package and peaks
with p value < 0.01 were defined as differential peaks. Differential peaks between TCF3ZNF384 versus ZNF384 were used to generate a heatmap and average profile for HA
signal at the peak regions. The same methods were used to compare differential histone
modifications, H3K4me1, H3K18Ac, and H3K27Ac; and TCF3-ZNF384 isoforms, with
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exon 8 versus without exon 8. qPCR (ΔΔCt method) was employed to validate ChIP-seq
results.
Differential binding sites were annotated to genes if their promoter (TSS +/- 2kb)
overlapped the binding sites and GSEA was performed using differentially expressed
genes from RNA-Seq analysis by their rank of log2 fold change. Enriched gene sets were
obtained through GREAT112 (version 4.0.4) using 1139 peaks identified as increased
binding in TCF3-ZNF384 compared to ZNF384 and 1128 peaks identified as increased
binding in TCF3-ZNF384 with exon 8 compared to without exon 8.

Motif analysis
For differential peaks, genomic sequences in fasta format were extracted from the
mouse genome based on the coordinates of peaks. Discriminative mode of MEME-ChIP
(http://meme-suite.org/tools/meme-chip) was used for motif analysis. To perform motif
enrichment analysis in ‘Fusion up’ peaks, the primary sequences were set to be fasta
sequences for ‘Fusion up’ peaks and the control sequences were set to be fasta sequences
for ‘Fusion down’ peaks. Similarly, for motif enrichment analysis in ‘Fusion down’
peaks, fasta sequences for ‘Fusion down’ peaks and ‘Fusion up’ peaks were set to be
primary and control sequences, respectively.

Immunoprecipitation and mass spectrometry (IP-MS)
Whole cell lysates from 100 X 106 ARF-null pre-B cells or HEK293T cells
expressing HA-tagged ZNF384 or fusions were prepared for immunoprecipitation (IP)
using HA-Tag Magnetic IP/Co-IP Kit (Pierce) according to manufacturer’s
recommendation. Input, flow-through, and immunoprecipitation was collected and
quantified using the BCA protein assay kit (Pierce). Samples were run on NuPAGE 412% Bris-Tris protein gel (ThermoFisher Scientific), stained with SimplyBlue™
SafeStain (Invitrogen) and submitted to the St. Jude Proteomics Shared Resource. The
proteins in the gel bands were reduced with dithiothreitol to break disulfide bond and the
Cys residues were alkylated by iodoacetamide to allow the recovery of Cys-containing
peptides. The gel bands were then washed, dried down in a speed vacuum, and
rehydrated with a buffer containing a protease to allow the protease to enter the gel.
Trypsin was used for overnight proteolysis. The next day, digested samples were
acidified and the peptides were extracted multiple times. The extracts were pooled, dried
down and reconstituted in a small volume. The peptide sample were loaded on a
nanoscale capillary reverse phase C18 column by a HPLC system (Thermo EasynLC
1000) and eluted by a gradient (~90 min). The eluted peptides were ionized by
electrospray ionization and detected by an inline mass spectrometer (Thermo Elite). The
mass spectrometry (MS) spectra were collected first and the 20 most abundant ions were
sequentially isolated for MS/MS analysis. This process was cycled over the entire liquid
chromatography gradient. Database searches were performed using Sequest search engine
in our in-house SPIDERS software package. All matched MS/MS spectra were filtered
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by mass accuracy and matching scores to reduce protein false discovery rate to ~1%.
Finally, all proteins identified in one gel lane were combined. The total number of
spectra, namely spectral counts (SC), matching to individual proteins may reflect their
relative abundance in one sample after the protein size is normalized. For binary
comparison, statistical analysis was performed using G-test113. MS results were analyzed
using the CRAPome online tools with default setting to determine Significance Analysis
of INTeractome (SAINT) score and fold change114,115.
To validate interactions, IP protein lysates (5ug of IP, 20ug of input, or 20ug of
flow-through) were run on NuPAGE 4-12% Bris-Tris protein gel at 160V for 1 hour.
Blots were probed with anti-HA (Abcam, Ab9110, 1:5000), anti-HCLS1 (Abcam,
Ab151511, 1:1000), anti-IKZF1 (Active Motif, 39292,1:500), anti-PARP1 (Cell
Signaling, CST9542, 1:1000), or anti-BAF (LSBio, LS-B447, 1:1000).

Results

Differential gene expression in cells expression ZNF384 fusions
ARF-null pre-B cells were lentivirally infected with CL20-MSCV-ires-GFP
plasmid (empty vector) or plasmid containing the inserts ZNF384-HA, TCF3-ZNF384HA, or TAF15-ZNF384-HA (Figure 5-1A). GFP positive cells were fluorescenceactivated cell sorted and protein expression was confirmed before performing
mechanistic assays (Figure 5-1B). To compare gene expression in wild type versus
fusion expressing cells, I submitted RNA for sequencing. I used differential analysis of
the transcriptomes to curate lists of the top 500 upregulated or downregulated genes in
fusion versus wild type samples (Figure 5-1C and Supplemental Data for Chapter 5). I
performed GSEA, including these curated lists, of ZNF384-rearranged and non-ZNF384rearranged patient RNA-seq samples and found that genes with upregulated expression in
ZNF384-rearranged ARF-null pre-B cells also had high expression in ZNF384rearrranged patients with a normalized enrichment score (NES) of 1.48 and p value of
0.014 for the combined fusion analysis (Figure 5-1D). The same correlation was seen
with the downregulated genes, validating that expression of ZNF384 fusions in vitro was
able to drive transcriptional deregulation similar to that seen in patients (Figure 5-1D).

Increased binding of ZNF384 fusion oncoproteins
Next, I used ChIP-seq to compare chromatin occupancy of ZNF384 and the
fusions. I first validated the HA antibody by performing ChIP-seq of ZNF384-HA using
anti-HA and anti-ZNF384. I found that the HA antibody did not have off-target binding
but surprisingly, was more sensitive than the ZNF384 antibody (Figure 5-2A, B). The
anti-HA antibody produced 3X more called peaks compared to anti-ZNF384, however, a
closer look at the reads revealed anti-ZNF384 did have signal in those regions (Figure
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Figure 5-1. The transcriptome of ARF-null pre-B cells expressing ZNF384 fusions
recapitulates the gene expression signature identified in patients.
(A) The workflow for mechanistic studies. ARF-null pre-B cells were transduced with
empty vector, wild type, or representative fusions and fluorescence-activated cell sorted
before performing RNA-seq, ChIP-seq, and IP-MS. (B) Samples analyzed for fusion
expression by anti-HA immunoblotting include: ARF-null pre-B cells expressing empty
vector, ZNF384 (kDa 65), TAF15-ZNF384 (kDa 78), or TCF3-ZNF384 (kDa 78). (C)
Differential gene expression from wild type expressing cells compared to fusion
expressing cells. (D) GSEA showing similarity of the gene expression profile of mouse
ARF-null pre-B cells expressing ZNF384 fusions to the gene expression profile of human
ZNF384-rearranged (ZNF384r) leukemia cells. Modified from final submission with
permission. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of
mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373-9.4
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Figure 5-2. Validation of HA antibody for ChIP-sequencing.
(A) Quantitative PCR (qPCR) analysis on ChIP samples to verify no off-target pulldown. Comparison of ARF-null cells overexpressing ZNF384 or ZNF384-HA and ChIP
using IgG, ZNF384, or HA antibody. (B) qPCR analysis of ChIP samples showing pulldown of Sip1 region by ZNF384 antibody compared to IgG. Pull-down was greater using
HA antibody. (C) The number of peaks identified using anti-HA compared to antiZNF384 showing the number of unique and overlapping peaks. (D) An IGV visualization
showing three genomic regions with binding of ZNF384. Peaks were called for anti-HA
samples but not anti-ZNF384 samples although minor peaks can be observed.
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5-2C, D). These were not off-target binding of anti-HA but instead, increased binding at
ZNF384 targets.
I then used anti-HA for ChIP-seq of HA-tagged ZNF384 or fusions. Heatmaps
that rank binding sites according to the strength of HA ChIP-seq signal revealed that
fusions had increased binding at 2,298 sites and decreased binding at 495 sites compared
to wild type (Figure 5-3A). Most of the differentially bound sites were not novel sites but
instead differed in strength of binding. I analyzed the 2,298 regions for motif enrichment
which identified ZNF384 and RUNX1/2/3 binding motifs, AAAAAA and AACCAC,
respectively (Figure 5-3B). Additionally, GREAT analysis of these regions showed an
enrichment for genes in pathways related to hematopoiesis and signaling (Figure 5-3C
and Supplemental Data for Chapter 5). One key pathway is stem cell maintenance, so I
manually validated genes with differential binding sites (Figure 5-3D). Many of these
genes also had slightly increased gene expression, although not statistically significant
(Figure 5-3E). To formally integrate the RNA- and ChIP-seq data, I curated gene lists of
genes with increased binding of the fusions in the promoter (Supplemental Data for
Chapter 5). I performed GSEA using these curated lists which revealed that promoters
with increased binding of the fusions also have increased gene expression with a NES of
1.78 and p value of 0.000 for the combined fusion analysis (Figure 5-3F).

Differential H3K27Ac at select sites with increased fusion binding
I next performed ChIP-seq of the histone marks H3K27Ac, H3K18Ac, and
H3K4me1 to investigate if expression of ZNF384 fusions alters the chromatin landscape.
I found no global differences in H3K4me1, H3K18Ac, or H3K27Ac (Figure 5-4).
Interestingly, I identified a subset of 47 regions that had increased binding of the fusions
and increased H3K27Ac (Figure 5-5A). In contrast to most fusion binding sites that
appear to be normal ZNF384 binding sites with increased binding of the fusions, these 47
regions appear novel to the fusions and H3K27Ac (Figure 5-5B, C). These sites are often
intergenic and intronic and have variable effect on nearby gene expression (Figure 5-5B,
C).

Comparison of chromatin occupancy of TCF3-ZNF384 exon 8 splicing isoforms
As described previously, ZNF384 has splicing isoforms that include or exclude
exon 8 which translates to 2 of the 8 zinc fingers (Figure 2-6A). I observed that patients
with ZNF384 rearrangements display distinct patterns of exon 8 splicing and that mouse
models comparing these splicing isoforms have differences in leukemia latency and gene
expression. To further characterize the mechanistic role of exon 8 retention or exclusion,
I used ChIP-seq to compare chromatin occupancy of TCF3-ZNF384 with or without exon
8. The isoform including exon 8 bound to 1128 more sites (Figure 5-6A and
Supplemental Data for Chapter 5). I observed that regions with increased binding of
the exon 8 isoform often were flanked by regions of decreased binding (Figure 5-6B).
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Figure 5-3. Differential chromatin binding of ZNF384 fusions and the
transcriptional consequence.
(A) Heat map showing the ChIP–seq signal, centered on ZNF384 peaks, of wild type
ZNF384 compared to TCF3-ZNF384 and TAF15-ZNF384 (top panels). Peaks with
increased binding of fusion proteins compared to wild type proteins (middle panels).
Peaks with decreased binding of the fusion proteins compared to wild type proteins
(bottom panels). (B) Differential motif analysis comparing regions with increased
binding of TCF3-ZNF384 versus regions with decreased binding. (C) Terms enriched for
by GREAT analysis of gene regions with increased binding of the fusions. Showing GO
Biological Processes (top panel) and Mouse Phenotype Single KO (bottom panel). (D)
Representative genomic regions with increased binding of the fusions compared to wild
type. (E) Representative expression in fragments per kilobase million (FPKM) of genes
with differential binding. Columns show means of three replicates ± SD. (F) GSEA
showing enrichment of genes whose promoters have increased binding by ZNF384
fusions in the GEP of ZNF384r versus wild type pre-B cells. Modified from final
submission with permission. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis
and cell of origin of mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373-9.4
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Figure 5-4. Differential H3K4me1, H3K18Ac, and H3K27Ac in cells expressing
ZNF384 or fusions.
Heat map showing the ChIP–seq signal, centered on ZNF384 peaks, of wild type
ZNF384 compared to TCF3-ZNF384 and TAF15-ZNF384 (top panels). Peaks with
increased binding of fusion proteins compared to wild type proteins (middle panels).
Peaks with decreased binding of the fusion proteins compared to wild type proteins
(bottom panels). Comparison of H3K4me1 signal (left three columns), H3K18Ac signal
(middle three columns), or H3K27Ac signal (right three columns) in cells expressing
ZNF384 or fusions.
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Figure 5-5. Differential H3K27Ac in cells expressing ZNF384 fusions.
(A) Heat map showing the ChIP–seq signal, centered on ZNF384 peaks, of wild type
ZNF384 compared to TCF3-ZNF384 and TAF15-ZNF384; and H3K27Ac signal,
centered on ZNF384 peaks (top panels). Peaks with increased binding of fusion proteins
compared to wild type proteins separated by regions with increased H3K27Ac or regions
with same H3K27Ac (middle panels). Peaks with decreased binding of the fusion
proteins compared to wild type proteins (bottom panels). (B) Representative genomic
region, Ikzf3, with increased binding of the fusion and increased H3K27Ac in the
intronic region (left panel). The FPKM of Ikzf3 (right panel). Columns show means of
three replicates ± SD. (C) Representative genomic region, Runx3, with increased binding
of the fusion and increased H3K27Ac in the intronic region (left panel). The FPKM of
Runx3 (right panel). Columns show means of three replicates ± SD.
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Figure 5-6. Differential chromatin binding of TCF3-ZNF384 splicing isoforms.
(A) Heat map showing the ChIP–seq signal, centered on ZNF384 peaks, of TCF3ZNF384 with exon 8 compared to TCF3-ZNF384 without exon 8 (top panels). Peaks with
increased binding with exon 8 compared to without exon 8 proteins (middle panels).
Peaks with decreased binding with exon 8 compared to without exon 8 proteins (bottom
panels). (B) Representative genomic regions with increased binding of the isoform with
exon 8. (C) Terms enriched for by GREAT analysis of regions with increased binding of
the fusion isoform with exon 8. Showing Go Biological Processes (top panel) and Mouse
Phenotype Single KO (bottom panel).
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GREAT analysis revealed that regions with increased binding were enriched for genes
involved in RNA stability or lymphocyte differentiation (Figure 5-6C). Interestingly,
loss of these genes in mouse models is correlated with phenotypes involving abnormal
neutrophil and granulocyte differentiation. In other words, genes with increased binding
of the TCF3-ZNF384 isoform with exon 8 have been shown as critical for normal
myelopoiesis.

Identifying proteins that interact with wild type ZNF384 and fusions
One possible mechanism for increased binding of the fusion proteins at known
ZNF384 sites is through novel protein interaction. To compare protein interactions
between ZNF384, TCF3-ZNF384, and TAF15-ZNF384 I used protein lysates from ARFnull pre-B cells for anti-HA immunoprecipitation followed by mass spectrometry (IPMS). Surprisingly, I identified proteins that interact with ZNF384 but had lower
interaction with the fusions (Figure 5-7A). Most often these proteins were transcription
factors important during hematopoiesis; MNDAL (myeloid cell nuclear differentiation
antigen-like, of which there is no commercial antibody), CUX1, IKZF1, and HCLS1
(hematopoietic lineage cell-specific protein); DNA repair proteins, PARP1, RFA1; and
cytoskeleton-related proteins, SVIL, VIME, ACTN4, BAF. I validated the interaction
with ZNF384 and HCLS1, IKZF1, PARP1, and BAF by Co-IP followed by western
blotting (Figure 5-7B, C). The fusions had reduced, or completely lost, pull-down of
these proteins. Additionally, IP-MS also identified interactions that favored the fusions
with ribosomal and lamina protein, although this could be non-specific interactions
(Figure 5-7A).

Discussion
I have shown that expressing ZNF384 fusions in mouse ARF-null pre-B cells
leads to a gene expression profile that resembles the ZNF384-rearranged patient
transcription signature. For the first time I have described the chromatin binding patterns
of these fusions, which remain at canonical ZNF384 binding regions but bind with a
higher intensity. Regions with increased binding of the fusions are enriched for the
RUNX1/2/3 family motif. This leads to the possibility that novel interaction of the
fusions with RUNX1/2/3 encourage increased binding at ZNF384 regions adjacent
RUNX1/2/3 regions. However, this hypothesis has not been investigated.
Although I did not identify global changes in H3K4me1, H3K18Ac, or H3K27Ac
upon expression of ZNF384 fusions, I identified a subset of less than 50 regions that had
increased binding of the fusions and increased H3K27Ac. Intriguingly, these sites appear
to have novel binding of the fusions compared to wild type ZNF384. The regions are
typically within introns or intergenic regions, indicative of putative enhancers. Further
characterization of these regions using H3K7Ac HiChIP will determine if they are
primed, poised, or active enhancers and what genes they regulate116. I speculate that these
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Figure 5-7. Identification of proteins that interact with ZNF384 and fusions.
(A) Scatter plot showing the fold change of spectral counts for wild ZNF384 or ZNF384
fusions immunoprecipitation followed by mass spectrometry (IP-MS) compared to empty
vector control samples (three replicates each). The dashed line indicates equal fold
change and the red circle indicates ZNF384. (B) Co-IP followed by immunoblotting to
validate pull-down of wild type or fusions (HA), HCLS1, or IKZF1 in ARF-null pre-B
cells. (C) Co-IP followed by immunoblotting to validate pull-down of wild type or
fusions (HA), PARP1, or barrier-to-autointegration factor (BAF) in HEK293T cells.
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regions are hematopoietic stem or progenitor cell-specific enhancers that are activated
inappropriately by ZNF384 fusion binding.
Remarkably, I found that TCF3-ZNF384 splicing isoforms, with or without exon
8, had differential binding. Inclusion of exon 8, which translates to 2 additional zinc
fingers, leads to increased binding at over 1000 sites. The implications for altered
binding, gene regulation, and phenotype will be discussed in detail in Chapter 6.
Additionally, IP-MS has identified protein interactions with ZNF384 that have not
been previously reported. These assays did not reveal any novel protein interactions for
the ZNF384 fusions; however, interactions could be transient and require crosslinking
before IP-MS to capture weak or temporary interactions. Additionally, quantitation is
challenging because wild type and fusion protein expression is not equal.
The challenge of unequal protein expression affects interpretation of ChIP-seq
and IP-MS data. Wild type ZNF384 is overexpressed in the cells but they express low
levels of the fusion proteins (Figure 5-1B). Despite this, I still observed that regions had
increased binding of the fusions. If this was repeated using chromatin from cells that had
“normalized” protein expression, I would likely observe more striking increases in fusion
binding. Moreover, I plan to repeat the IP-MS experiments using “normalized” lysates
with the hope of identifying novel interactions.
The second major challenge in these mechanistic studies is the cell-type. As
mentioned previously, a great deal of evidence supports the cell of origin being a HSPC
for ZNF384-rearranged leukemia. Consequently, the chromatin state and proteins
expressed in HSPCs are likely the most permissive environment for ZNF384 fusions to
transform cells. I could only identify fusion protein expression in ARF-null pre-B cells
and therefore had to perform all mechanistic experiments using those cells. It is probable
that these experiments fail to capture key changes in chromatin binding, histone
modifications, and protein interactions. Remarkably, in light of these major challenges, I
was able to reveal several fusion-specific characteristics.
Finally, this portion of my project has highlighted the value and importance of
basic research. Information about the normal function of ZNF384 is limited primarily to
osteoblasts. It has been difficult to interpret the results and hypothesize the mechanism of
the fusions without knowledge of wild type ZNF384, especially its role in hematopoiesis.
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CHAPTER 6.

DISCUSSION

The key aims of this project were to investigate the interplay between ZNF384
fusion oncoproteins, representing different N terminal fusion partners and splicing
isoforms with concomitant genetic alterations, cell of origin, and additional stimuli - such
as proliferative stress or cytokine stimulation - in the genesis of lineage-ambiguous
leukemia. Additionally, I sought to understand how these fusions function as
oncoproteins that drive the distinct gene expression profile observed in ZNF384rearranged leukemia. I have shown that expression of ZNF384 fusions had the greatest
effect in hematopoietic stem and early progenitor cells and promotes expansion of
immature myeloid cells vitro and leukemia development in vivo. Interestingly, I also
showed differences in tumor characteristics dependent on fusion partner, splicing isoform
usage, and donor cell species. Mechanistic studies revealed that ZNF384 fusions bind to
canonical ZNF384 sites with higher avidity and a subset of these sites also have novel
H3K27Ac, suggestive of aberrant enhancer activation. While providing mechanistic
insights into the role of ZNF384 lesions in leukemogenesis, this work has generated new
questions for future study. These include: what is causing increased binding of the
fusions to target DNA sequences? What is the normal role of ZNF384 in hematopoiesis?
Finally, are these regions with increased H3K27Ac enhancers?

Expression of ZNF384 Fusions in a Hematopoietic Progenitor Cell of Origin
Promotes an Immature Myeloid Bias and Drives Leukemia Development
Using multiple approaches, I have shown that expression of ZNF384 fusions in
HSPCs perturbed normal hematopoietic development with skewing to immature myeloid
or B/myeloid populations and induced leukemia when transplanted into mice. Mouse
colony forming unit assays revealed that in myeloid growth conditions, expression of
most of the fusions tested led to sustained self-renewal and an immature myeloid
immunophenotype. In vivo changes in hematopoiesis could not be investigated with the
viral transplant models because of poor engraftment of fusion-expressing cells. However,
using the Ep300-Zfp384-V5-HA GEMM I observed a block in lymphoid cell
differentiation and an expansion of myeloid cells in the peripheral blood. This skewing of
differentiation was observed in immature hematopoietic cells also, with expansion of
GMP and CMP compartments. Moreover, human CD34 cells that express ZNF384
fusions differentiated into CD45, CD33 double positive cells with half of the cells also
expressing CD19. When cells were sorted into stem and progenitor compartments, only
HSCs expressing TCF3-ZNF384 had increased colony forming ability. The
immunophenotype observed in the bulk assay - CD45+ CD33+ - was recapitulated by
HSC, MPP, and CMP cells. In contrast, MEP and GMP cells expressing the fusion had a
colony forming disadvantage. Together these experiments support that expression of
ZNF384 fusions in a subset of hematopoietic stem and progenitor cells leads to reduced
lymphoid expansion and an abundance of immature, myeloid lineage-primed cells
(Figure 6-1). Consistent with this, sorting HSPC compartments prior to transduction
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Figure 6-1. Model for ZNF384-rearrangment driven cellular transformation.
Normal mouse hematopoiesis (top panel). In contrast to the mouse, human progenitors
retain multi-lineage abilities until later in differentiation (not shown). A proposed model
for how acquisition of ZNF384 rearrangements leads to skewed hematopoiesis and
leukemic vulnerability (bottom panel). An HSC acquires a ZNF384 rearrangement which
leads toward a propensity for CMP and GMP differentiation, over other progenitor cells,
and an accumulation of immature myeloid cells (CD45+ and CD33+). A second hit or
stimulus is required to transform cells into leukemia. In mouse this is restricted to AML
only, in human cells the leukemia is B/Myeloid.
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revealed that the HSC compartment was most sensitive to cellular transformation by
TCF3-ZNF384. With increasing maturation, cells they were less responsive to ZNF384
fusions, which is also supported by the lack of phenotype in the ARF-null pre-B cells
expressing ZNF384 fusions. In contrast, other fusion oncoproteins observed in pre-B
ALL induce transformation in ARF-null mouse pre-B cells suggesting a B-lineage cell to
be the cell or origin80. These findings support that the fusions alone, and not concomitant
lesions, drive lineage aberrancy and that this lineage aberrancy is dependent on the
correct cell of origin, which together suggests that the cell of origin for both B/myeloid
MPAL and pre-B ZNF384r ALL is a primitive hematopoietic cell. This is supported by
the human genomic data showing convergence of all modalities of genomic data for both
entities and the common observation of lineage ambiguity in ZNF384r ALL that does not
fulfill criteria for a diagnosis of B/myeloid MPAL16,25,29.
Transplantation of mouse or human HSPCs expressing ZNF384 fusions led to
development of acute leukemia and several observations suggested that cooperation
between the cell-of-origin, specific fusion protein, secondary hits, pressure to expand,
and recipient microenvironment was important for leukemia formation (Figure 6-1).
Mouse HSPCs lentivirally expressing the fusions required an additional hit, NRAS
G12D, and developed into AML in vivo. In contrast, ARF-null pre-B cells were
unaffected by fusion expression during transplantation experiments, again, supporting a
primitive hematopoietic cell as the cell of origin. When Ep300-Zfp384-V5-HA GEMM
bone marrow cells were transplanted into recipient mice, they developed AML without a
second hit, although, in their native environment they did not become leukemic. This
could be caused by the pressure to expand during the transplantation process, evolution of
additional genetic alterations promoting leukemic fitness, or differences in the recipient
microenvironment, due to irradiation.
Human cells expressing TCF3-ZNF384 transplanted into NSG-SGM3 mice that
express the human cytokines SCF, GM-CSF, and IL-3 led to the development of
B/myeloid MPAL, however, no leukemia was observed in NSG mice or when using
EP300-ZNF384 or TAF15-ZNF384. Thus, it is likely that expression of these human
cytokines played a role in transformation which is supported by the lack of tumors in
NSG mice. Additionally, the differences in mouse-derived or human-derived tumors
(immunophenotype, second-hit requirement) could be caused by variances between
organismal hematopoiesis and gene conservation, with human CD34 cells being the more
appropriate system to investigate human fusion genes. In both the human CFU assay and
transplantation experiments, we observed expression of CD19 and CD33, which was not
observed in any experiments using mouse cells. It is possible that there are differences
between human and mouse early stem and progenitors, in which human cells are
permissive to lineage ambiguity but mouse progenitors are more restrictive91,117. Another
explanation could be the type of cells used, with the human cells being derived from cord
blood and the mouse cells being derived from adult bone marrow. Mouse CFU or
transplantation assays using cells derived from fetal liver could produce a different
immunophenotype. In the experiments described, the mouse system was best for
determining how fusions alter hematopoietic development and which fusions and colesions drove leukemia, but the human CD34 system, although technically more onerous
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and reproducibly less robust in inducing transplantable leukemia, was best for
demonstrating lineage ambiguity, a key goal of the project. The proposed model was
based on the mouse data, since differentiation results are more robust, however, the
human differentiation is likely slightly different to permit CD19 expression (Figure 6-1).

Increased Binding of ZNF384 Fusions at Genes Encoding Regulators of
Hematopoiesis Leads to Skewed Hematopoiesis
To understand how ZNF384 fusions skew hematopoiesis and prime cells for
leukemic transformation, I used multiple assays including RNA-seq, ChIP-seq to
determine fusion protein occupancy and changes in histone modifications, and IP-MS to
identify protein interactions. TCF3-ZNF384 and TAF15-ZNF384 had increased binding
at over 2000 sites, most being canonical ZNF384 binding sites with an enrichment for the
RUNX family motif. Loci were enriched for genes involved in regulation of
hematopoiesis which suggests that ZNF384 has a role in transcription regulation of
lineage-specific programs, although knockout mouse models show normal hematopoietic
output except two fold increase in CD8 positive T cells 43. Binding of ZNF384 fusions
alters this fine-tuned regulation and leads to skewed hematopoiesis (Figure 6-2). We also
identified a subset of regions with increased binding of the fusions, very little wild type
ZNF384 binding, and increased H3K27Ac. These regions were intronic and intergenic
which supports that they are putative enhancers. I hypothesize that these regions are
hematopoietic stem or progenitor-specific enhancers that are being inappropriately
activated by ZNF384 fusions in the ARF-null pre-B cell (Figure 6-2). In the context of
cellular transformation in patients, it is possible that ZNF384 fusions arise in an HSC and
inappropriately retain HSC enhancers activity as the cells attempt to differentiate. This
produces the conundrum of an immature cell that also expresses the mature markers,
CD19 and CD33 (Figure 6-2). However, the role of increased H3K27Ac in leukemic
transformation and the validation that these are enhancer regions needs to be further
investigated. These regions should be characterized using H3K27Ac HI-ChIP to
determine the promoters that directly interact with these regions. This would not only
provide insight into the mechanism of the fusions but is also of particular interest
considering a publication that reported global loss of H3K27Ac in cells expressing
ZNF384 fusions and suggests treatment with an HDACi 34.

Is ZNF384 an Important Regulator of Normal Hematopoiesis?
Several questions remain regarding the mechanism of ZNF384 and ZNF384
fusions in hematopoiesis. The expression of ZNF384 throughout hematopoiesis and the
high prevalence of ZNF384 rearrangements in leukemia with a distinct
immunophenotype and gene expression profile suggest that ZNF384 is an important
regulator of normal hematopoietic development. Additionally, two fusion partners,
TAF15 and EWSR1, are rearranged with transcription factors in other cancer types, solid
tumors and leukemias, where the C-terminal partner is specific to cancer cell type, which
also supports that ZNF384 has a role in hematopoietic development 8. ZNF384 knockout
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Figure 6-2. The proposed mechanism of ZNF384 fusion-driven transcriptional
deregulation.
Transcriptional regulation in HSPCs (top panel). Stem and progenitor cell enhancers are
active and influencing expression of progenitor-related genes. Differentiation-related are
silenced. Transcriptional regulation in pre-B cells (middle panel) where the stem and
progenitor cell enhancers are now silent and differentiation-related genes are now
actively transcribed. Transcriptional regulation in ZNF384-rearranged cells (bottom
panel). The ZNF384 rearrangement occurs in an HSPC where the stem and progenitor
cell enhancers are active, ZNF384 fusions bind to maintain expression of progenitorrelated genes. ZNF384 fusions also bind to the differentiation-related genes that wild type
ZNF384 binds, and deregulates this precise control of lineage-specific gene expression.
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mice have a reportedly normal hematopoietic system but preserved expression of the
homolog, ZNF362, could mask the phenotype. Through integrated analysis of ZNF384
ChIP-seq data from 4 unrelated cell lines, it was found that binding regions shared
between all cell lines were enriched for regions bound by proteins that contribute to
maintenance of stem/progenitor pluripotency/multipotency and the poised gene state 51. It
is possible that ZNF384 regulates cell-type specific gene expression through interaction
with co-factors. Specifically, the impact of ZNF384 in hematopoiesis is facilitated by
interaction with hematopoietic-specific co-factors which regulate binding, along with the
consensus sequence, and lead to cell-type specific gene regulation. No such proteins were
identified from my IP-MS analysis; however, the pre-B stage could be too late in
development for expression of stem/progenitor-regulating co-factors. The IP-MS data did
reveal that ZNF384 interacts with many cytoskeleton proteins, including BAF, or barrierto-autointegration factor, which regulates chromatin organization at the nuclear
membrane. It is possible that through these interaction partners, ZNF384 regulates gene
expression by altering chromatin organization at the nuclear membrane.

What Causes Increased Binding of the Fusion Proteins to Canonical ZNF384 Sites?
It is likely that the N terminal portion of the fusions can interact with co-factors
that stabilize the protein, which leads to increased binding of the fusion proteins at
canonical ZNF384 sites. However, my attempt at exploring this option using IP-MS did
not support this hypothesis. As mentioned previously, there were technical issues
regarding protein abundance and cell-of-origin, so this warrants further exploration.
Protein abundance could be normalized prior to IP in order to compensate for differences
in fusion and wild type protein levels. Additionally, using a more relevant cell type, such
as lentivirus-induced tumor material, would be a reasonable endeavor to identify cell type
specific interactions. An alternative mechanism of increased binding is through liquidliquid phase separation118-121. The N-terminal portions of TAF15-ZNF384 and EWSR1ZNF384 contain intrinsically disordered regions and have been shown, when fused with
other C-terminal partners, to be critical for phase separation and cellular transformation
95,122
. Specifically, EWSR1-FLI1, but not wild type FLI1, phase separate with the BAF
chromatin remodeling complex, bind tumor specific enhancers, and activate expression of
oncogenic gene programs. Analysis of all ZNF384 fusion sequences using a phase
separation prediction algorithm revealed that all fusions are likely to phase separate and
are therefore being assessed for the ability to form liquid-like condensates and the
implications for transcriptional regulation (data not shown). A broad mechanism, such as
phase separation, that is based on protein properties rather than specific domains is more
likely to cause the common gene expression profile and phenotype driven by the diverse
range of N terminal partners in ZNF384 fusions.
The challenge remains that changes in transcriptional programs are cell-type
specific and it is probable that the model used to characterize chromatin occupancy,
ARF-null pre-B cells, does not capture the full complexity of what is happening in
leukemic cells. Extensive characterization of the available cellular systems could not
detect fusion expression by immunoblotting in any cell type more immature than the
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ARF-null pre-B cells. ChIP-seq experiments in HSPCs or experimental tumors were not
attempted due to lack of fusion detection by immunoblot, however, they should be tried
in the future given that the well-studied KTM2A fusions also cannot be detected by
immunoblot but produce high quality ChIP-seq data 123,124. Additionally, bone marrow
cells from the Ep300-Zfp384-V5-HA GEMM are potentially an attractive model for
further mechanistic studies, however, the protein expression must be characterized. It
would be interesting to sort hematopoietic cells into stem and progenitor compartments
and compare fusion binding. This would further explore why early stem and progenitor
cells are more sensitive to fusion expression compared to later, committed progenitors.

ZNF384 Fusions Alter Hematopoietic Transcriptional Programs Toward Immature
Myeloid Signatures
Despite the lack of transformation in ARF-null pre-B cells expressing ZNF384
fusions, it was clearly demonstrated that the fusions induced deregulation of similar
genes observed in human leukemia and that a substantial proportion of these genes are
targets of increased binding of the fusions. Additionally, gene expression analysis of
tumors induced by lentiviral expression of ZNF384 fusions into mouse or human HSPC
revealed similarities to ZNF384-rearranged patient gene expression signatures.
Interestingly, using sc-RNA-seq of Ep300-Zfp384-V5-HA bone marrow I also observed
that cells had a shift from HSPC towards immature myeloid cells with reduced
maturation compared to wild type bone marrow. This nicely supports the modeling data
which showed a shift towards myeloid differentiation without reaching maturation and
permitted sustained self-renewal, aberrant lineage marker expression, and
leukemogenesis.

Alternative Splicing Isoforms of TCF3-ZNF384 Drive Distinct Transcriptional
Programs, Leading to Different Leukemia Phenotypes
Detailed analysis of patient transcriptomes revealed differential splicing isoforms
of ZNF384 fusions. Fusions preferentially exclude exon 8 of ZNF384, which encodes 2
zinc finger domains. To investigate the functional role of these isoforms, I performed a
transplant experiment to compare cells expressing TCF3-ZNF384 with or without exon 8.
Mice transplanted with cells expressing ZNF384 fusions lacking exon 8 had a shorter
latency of leukemia, higher peripheral blood white blood cell count, and lower Gr1
expression suggesting that cells were less immature and more monocytic. Surprisingly,
tumor transcriptomes also differed between the isoforms, with higher expression of the
stem cell marker, Kit, and the myeloid cell marker, Mpo, seen in tumors with exon 8.
This supports that expression of the TCF3-ZNF384 isoform with exon 8 leads to a more
stem-like, quiescent phenotype compared to the isoform lacking exon 8. It would be
interesting to investigate how these isoforms differ in cell cycling, response to treatment,
and if there is a shift in isoform usage, or Mpo expression, at relapse.
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The expression of Mpo being dependent on fusion isoforms has major
implications for tumor diagnostics, and therefore treatment. MPO expression is the
marker that distinguishes B-ALL with aberrant myeloid marker expression (CD13,
CD33) from B/Myeloid MPAL 12. ZNF384-rearranged leukemia is characterized by
expression of both B-cell and myeloid marker expression and was thought to be two
different diseases, B-ALL or MPAL. However, recent genomic, transcriptome, and cellof-origin evidence supports that ZNF384-rearranged leukemia is a single entity with
variation in MPO expression16. Additionally, I showed that exon 8 inclusion was higher
in patients diagnosed as B/myeloid MPAL compared to B-ALL (Figure 2-3). This is
important because diagnosis of leukemias determines treatment protocol. These
experiments suggest that increased MPO expression is a consequence of ZNF384 fusion
isoform usage and should not be used as a diagnostic marker in ZNF384-rearranged
leukemia.
ChIP-seq was performed to compare the binding of the TCF3-ZNF384 isoforms
and found the isoform with exon 8 had increased binding at over 1000 regions. These
regions were enriched for lymphocyte differentiation pathways, suggesting that
abundance of isoform expression could alter cellular lineage. Interestingly, the sites with
increased binding of the isoform including exon 8 were often flanked by regions with
decreased binding. This pattern of altered binding could mean that the isoform lacking
exon 8 needs to dimerize in order to bind, hence two adjacent peaks. In contrast the
isoform with exon 8, and therefore 2 additional zinc fingers, has stronger affinity for the
same region and is able to bind as a monomer, hence the single peak.

Specific ZNF384 Fusions are Associated with Unique Characteristics
Although all fusion partners drive a similar gene expression signature in patients,
some notable phenotypic differences have been observed. As mentioned previously, there
are differences in fusion partner frequency with the most common partners being EP300
and TCF3 (Table 1-1). Additionally, TCF3-ZNF384 fusions occur in younger patients
with multiple reports in infants and no cases in adults. TCF3 fusions also are the only
ones that do not always preserve full length ZNF384, with breakpoints reported at exons
2 (full-length), 3 (full-length), 5 (missing leucine zipper), and 7 (missing leucine zipper,
S/T rich, Proline rich, and NLS) (Figure 1-2). Interestingly, the breakpoints that lose
portions of ZNF384 have retained additional domains from TCF3. Specifically, when full
length ZNF384 is retained, TCF3 only contributes a transactivation domain (up to exon
11). When the fusion occurs at exon 5 of ZNF384, TCF3 contributes 2 transactivation
domains (up to exon 13) and when the fusion occurs at exon 7 of ZNF384, TCF3
contributes a ubiquitin ligase domain and a helix-loop-helix domain (up to exon 17 or
18). This suggests that all the domains of ZNF384 are important for cellular
transformation by ZNF384 fusions and that there are similarities in TCF3 domains that
can compensate for loss of ZNF384 domains.
Viral expression of ZNF384 fusions, but not wild type, was challenging due to
low transduction efficiency and required careful optimization. Even with optimization,

90

EP300-ZNF384 produced low titer virus and fusion expression was lost in multiple
experimental models. In the mouse CFU assays I did not observe serial replating with
TCF3-ZNF384 expression, but did with TAF15-ZNF384, EP300-ZNF384, and
CREBBP-ZNF384. TCF3-ZNF384 expressing cells were more differentiated compared
to the cells expressing other fusions. In the transplant models, TCF3-ZNF384 and
TAF15-ZNF384 produced Mac1, Gr1 double positive AML when co-expressed with
NRAS G12D. While EP300-ZNF384 also produced AML, the immunophenotype lacked
Gr1 expression and had more lymphoid marker expression. In the human CFU assays,
TAF15-ZNF384 and EP300-ZNF384 produced a similar stem-like immunophenotype but
TCF3-ZNF384 cells were myeloid progenitors. Conversely, in CD34 transplantation,
only TCF3-ZNF384 expressing cells were able to develop leukemia. Overall, the more
aggressive leukemia observed experimentally could explain the earlier onset in patients
while the other fusions drive sustained self-renewal and a slower progression to
leukemia. These phenotypic differences raise the possibility of differences in mechanisms
of leukemogenesis that should be investigated further by comparing chromatin binding
differences and protein interaction differences between fusion partners. Although, this
was technically challenging in my experience, hopefully future ZNF384-rearranged
models will be able to address this question.

ZNF384-rearranged Leukemias Retain a Stem Cell-like Phenotype
Another interesting observation about ZNF384-rearranged leukemia that has
implications for treatment and interpretation of experiments is the stem cell-like
phenotype. In patients, it has been reported that there is an upregulation of expression of
HSPC signatures and down regulation of cell cycle pathway genes 29,30. There are also
reports of patients with ZNF384 fusions relapsing 10-13 years after achieving complete
remission 125. Together, this leads to the possibility that cells expressing ZNF384 fusions
can maintain a quiescent state and may require stimuli to develop leukemia. This is
highlighted by some of my experimental observations while working on this project.
First, the only cell line that expresses ZNF384 fusions, JIH-5, was established from a
patient with B/myeloid MPAL driven by EP300-ZNF384 126. Remarkably, this cell only
divides every 10 days. Additionally, numerous patient derived xenografts have been
attempted for ZNF384-rearranged leukemia as part of St. Jude PROPEL and only one
tumor has engrafted. Moreover, as mentioned previously, secondary tumor engraftment
in my mouse transplantation models is very rare. The implications of this would require
modified therapeutic protocols for treating ZNF384-rearranged patients because
quiescent cells are challenging to treat with conventional chemotherapy.
Overall, this project developed a variety of human and mouse models to
comprehensively investigate how ZNF384 fusions skew hematopoiesis and prime cells
for leukemic transformation. I have established the first model of ZNF384-rearrangement
driven MPAL. Additionally, the serially transplantable tumors and GEMM are useful
tools for future therapeutic studies or continued mechanistic studies. Interestingly, this
work has highlighted the variation in phenotype between mouse and human models and
support that human CD34 cells are an appropriate model for investigating MPAL.
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Although the mechanism of transcriptional dysregulation is not completely clear yet, the
results reported here have begun to reveal the mechanism and hopefully are useful for
guiding further investigation with the ultimate goal of identifying therapeutic targets.
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APPENDIX A. CHAPTER 2 PRIMERS AND WES COVERAGE AND CALLS

Table A-1.

Primers used for breakpoint validation and cloning.

Primer name
EP300-ZNF384_fus_F1
EP300-ZNF384_fus_R1
EP300-ZNF384_fus_F2
EP300-ZNF384_fus_R2
ARID1B-ZNF384_Fus_F1
ARID1B-ZNF384_Fus_F2
SMARCA2-ZNF384_Fus_F1
SMARCA2-ZNF384_Fus_F2
TAF15-ZNF384_Fus_F1
TAF15-ZNF384_Fus_F2
CREBBP-ZNF384_Fus_F1
CREBBP-ZNF384_Fus_F2
CREBBP-ZNF384_Fus_R1
CREBBP-ZNF384_Fus_R2
TCF3-ZNF384_Fus_F1
TCF3-ZNF384_Fus_F2
TCF3-ZNF384_Fus_R1
TCF3-ZNF384_Fus_R2
TCF3-ZNF384_Fus_F3
TCF3-ZNF384_Fus_F4
TCF3-ZNF384_Fus_R3
TCF3-ZNF384_Fus_R4
TCF3-ZNF384_Fus_F5
TCF3-ZNF384_Fus_R5
EP300-ZNF384_Cloning_F
CREBBP-ZNF384_Cloning_F
TAF15-ZNF384_Cloning_F
TCF3-ZNF384_Cloning_F
ZNF384_Cloning_F
ZNF384_Cloning_R
Ep300_i6_LOXP F01
Zfp384_i2_LOXP_R02

Sequence (5’→3’)
TTCTCGACAAATCATTTCACACTGG
GAAGGCCAGAAGTACGGGTTAGAAT
CATTTGCTATGGACAAAAAGGCAGT
TGATTGACTCCCTTCTCTTCTCCAC
ACTTATGGCTTCCAGCTCTCCCTAC
GTATGGGTATCAGTGCCAACAACC
CAGCTTCGAGCTCAGATTTTAGCTTAT
AATGGATCAACACAGCCAAGGTTAT
ATAATAACCAGGGACAGCAGCAAAA
GCTATGGACAAGCATCACAAAGCTA
CACAACCTGTGAGACCTCCAAATG
GGAGCCATCTAGTGCATAAACTCGT
GGGAAGAGCTGAGACAATCATGG
GCATCTCCGACTTGGAGTAGAATGT
ATCTGCATCCTCCTTCTCCTCAG
CACCCAGCTCAGGTGAGGACTAC
GAAGGTCTGAGCTGATGATGCTGT
GCATCTCCGACTTGGAGTAGAATGT
GGCCTGCAGAGTAAGATAGAAGACC
GATCTACTCCCCGGATCACTCAAG
CTCTAGTGAGGCTGCATCCGTGTA
TATACGGGGTCAGGTCAAAGGAAC
CTCCCGACTCCTACAGTGGGCTA
GCATCTCCGACTTGGAGTAGAATGT
GGATTCTGGTTTTCCTCGCTTG
TTCGCGAGCAGGTGAAAATG
GGCCGTTAGTCATGTCGGATT
GCCCCAGGAGAATGAACCAG
ATGGAAGAATCTCACTTCAATTCTA
GGTGGCAGCACGGATCTCTA
GCTGCTCTTGGACTACCCTA
ACTCCTCCAAGTCGTCCTGA
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Table A-2.

WES exon coverage.

Sample

Reads

Mapped

Mpd
%

DupReads

Dup
%

Depth

≥1X

≥10X

≥20X

≥30X

≥40X

>=50X

>=60X

>=70X

>=80X

>=90X

>=100X

SJMMAML066067

278,456,520

277,828,740

99.77

49,803,925

17.93

240.63

99.30

95.32

94.40

93.63

92.83

91.91

90.81

89.47

87.86

85.95

83.74

SJMMAML066068

292,688,142

291,959,830

99.75

74,293,114

25.45

241.17

98.88

95.29

94.44

93.74

93.00

92.16

91.18

90.00

88.55

86.84

84.83

SJMMAML066069

294,323,528

293,760,107

99.81

47,781,762

16.27

255.93

99.46

95.47

94.51

93.78

93.02

92.18

91.21

90.06

88.70

87.06

85.17

SJMMAML066070

274,582,302

273,957,290

99.77

43,233,440

15.78

243.09

99.07

95.14

94.21

93.44

92.62

91.68

90.58

89.25

87.63

85.73

83.55

SJMMAML066071

277,725,112

277,154,973

99.79

55,248,297

19.93

247.82

98.71

95.03

94.16

93.41

92.60

91.68

90.56

89.20

87.56

85.62

83.36

SJMMAML066072

265,875,116

265,201,144

99.75

71,916,649

27.12

206.65

98.66

94.97

94.04

93.21

92.28

91.17

89.79

88.06

85.93

83.41

80.51

SJMMAML066073

304,733,422

303,987,006

99.76

61,745,663

20.31

241.06

99.26

95.30

94.34

93.61

92.84

91.95

90.89

89.59

88.03

86.16

84.00

SJMMAML066074

282,707,220

281,958,099

99.74

50,074,017

17.76

245.51

99.12

95.16

94.25

93.51

92.73

91.82

90.76

89.46

87.90

86.04

83.88

SJMMAML066075

261,390,002

260,606,140

99.7

57,299,021

21.99

205.79

99.18

95.06

94.03

93.09

92.02

90.72

89.10

87.10

84.63

81.77

78.54

SJMMAML066076

282,997,780

282,413,185

99.79

48,394,048

17.14

238.15

99.41

95.33

94.34

93.56

92.72

91.75

90.57

89.14

87.43

85.41

83.06

SJMMAML066077

275,093,812

274,375,762

99.74

74,950,577

27.32

209.18

99.03

95.19

94.26

93.43

92.51

91.40

90.02

88.30

86.21

83.73

80.88

SJMMAML066078

269,183,582

268,367,338

99.7

54,722,681

20.39

219.64

99.22

95.25

94.30

93.47

92.56

91.47

90.15

88.51

86.50

84.15

81.42

SJMMAML066079

276,391,652

275,766,849

99.77

53,475,067

19.39

230.89

99.29

95.25

94.24

93.41

92.50

91.45

90.16

88.60

86.72

84.50

81.95

SJMMAML066080

235,339,226

234,838,771

99.79

57,489,412

24.48

191.05

98.71

95.09

94.08

93.10

91.92

90.45

88.57

86.24

83.41

80.14

76.48

SJMMAML066083

273,884,514

273,004,935

99.68

53,190,987

19.48

233.61

98.96

95.07

94.17

93.41

92.58

91.62

90.47

89.06

87.36

85.34

83.01

SJMMAML066084

277,045,436

276,431,578

99.78

59,925,773

21.68

228.88

98.88

95.10

94.20

93.43

92.58

91.59

90.42

88.98

87.23

85.14

82.72

SJMMAML066085

285,253,198

284,652,473

99.79

52,700,768

18.51

244.41

99.08

95.20

94.29

93.57

92.80

91.92

90.88

89.61

88.07

86.23

84.11

SJMMAML066088

256,791,796

256,277,786

99.8

59,981,907

23.41

213.14

98.85

95.14

94.21

93.38

92.47

91.39

90.04

88.37

86.33

83.90

81.10

173_BM_KD023

246,895,162

246,624,967

99.89

76,616,387

31.07

189.66

98.28

94.79

93.74

92.69

91.46

89.90

87.91

85.42

82.45

79.05

75.27

182_BM_KD023

298,932,434

298,611,796

99.89

104,277,576

34.92

215.74

98.56

95.06

94.11

93.26

92.31

91.19

89.80

88.10

86.02

83.55

80.67

65_BM_KD022

281,882,080

281,588,349

99.9

89,499,213

31.78

209.67

98.73

95.14

94.17

93.29

92.31

91.13

89.68

87.84

85.62

83.00

79.99

67_SPL_KD029

249,974,838

249,722,705

99.9

83,117,692

33.28

186.38

98.43

94.94

93.87

92.83

91.57

89.97

87.95

85.40

82.36

78.84

74.95

515_SPL_KD025

250,429,758

249,914,176

99.79

60,134,939

24.06

224.22

98.02

94.91

94.00

93.19

92.30

91.25

89.95

88.36

86.40

84.07

81.40

522_BM_KD025

249,089,878

248,623,495

99.81

57,616,991

23.17

226.44

98.08

94.92

94.05

93.25

92.38

91.36

90.09

88.53

86.61

84.32

81.69

82_BM_KD025

262,169,200

261,677,828

99.81

64,568,617

24.67

227.41

98.24

95.08

94.21

93.46

92.66

91.72

90.56

89.09

87.29

85.13

82.61

CTRL_BM_KD023

224,703,672

224,289,431

99.82

52,242,820

23.29

200.02

98.23

95.04

94.03

93.08

91.97

90.55

88.73

86.44

83.70

80.51

76.95
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APPENDIX B. CHAPTER 3 CRISPR PRIMERS

Table B-1.

CRISPR primers used to generate GEMM.

Primer name

Sequence (5’→3’)

Zfp384-i2-LOXP-Guide 01
Zfp384-i2-lox66-HDR

taatacgactcactataggTTCCTTGGTATGAGATTGACgttttagagctagaaatagca
atctgggggcaccatttgcattgcagtttagccatgaccttcattcttggctgtccagtctaccgttcgtataatgtatgctat
acgaagttatgtcgacaatctcataccaaggaatatatggatttcggataacttatcagtagaaaggtagttatagctttt
TGAACCCTGGAGAGAGTGGT
ACTCCTCCAAGTCGTCCTGA
taatacgactcactataggAATGAGATCACTCGGGGTAAgttttagagctagaaatagca
cttccttttgttcttcatagttgagtttgaatttccagagatgtgtcttatggacctttaataacttcgtataatgtatgctatacg
aacggtactcgagccccgagtgatctcattggccaaccctagttgttcttgttttacttttgttttttcagac
GCTGCTCTTGGACTACCCTA
GAATACTTCTTGCAGGTACTACAGC

Zfp384_i2_LOXP_F01
Zfp384_i2_LOXP_R02
Ep300_i6_LOXP-Guide 01
Ep300_i6_lox71-HDR
Ep300_i6_LOXP F01
Ep300_i6_LOXP_R02
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